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Abstract
Developmental and/or epileptic encephalopathies (DEEs) are a group of devastating genetic disorders, resulting in early-
onset, therapy-resistant seizures and developmental delay. Here we report on 22 individuals from 15 families presenting with 
a severe form of intractable epilepsy, severe developmental delay, progressive microcephaly, visual disturbance and similar 
minor dysmorphisms. Whole exome sequencing identified a recurrent, homozygous variant (chr2:64083454A > G) in the 
essential UDP-glucose pyrophosphorylase (UGP2) gene in all probands. This rare variant results in a tolerable Met12Val 
missense change of the longer UGP2 protein isoform but causes a disruption of the start codon of the shorter isoform, which 
is predominant in brain. We show that the absence of the shorter isoform leads to a reduction of functional UGP2 enzyme 
in neural stem cells, leading to altered glycogen metabolism, upregulated unfolded protein response and premature neuronal 
differentiation, as modeled during pluripotent stem cell differentiation in vitro. In contrast, the complete lack of all UGP2 
isoforms leads to differentiation defects in multiple lineages in human cells. Reduced expression of Ugp2a/Ugp2b in vivo 
in zebrafish mimics visual disturbance and mutant animals show a behavioral phenotype. Our study identifies a recurrent 
start codon mutation in UGP2 as a cause of a novel autosomal recessive DEE syndrome. Importantly, it also shows that 
isoform-specific start-loss mutations causing expression loss of a tissue-relevant isoform of an essential protein can cause 
a genetic disease, even when an organism-wide protein absence is incompatible with life. We provide additional examples 
where a similar disease mechanism applies.
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Introduction
Developmental and/or epileptic encephalopathies (DEEs) 
are a heterogeneous group of genetic disorders, charac-
terized by severe epileptic seizures in combination with 
developmental delay or regression [49]. Genes involved in 
multiple pathophysiological pathways have been implicated 
in DEEs, including synaptic impairment, ion channel altera-
tions, transporter defects and metabolic processes such as 
disorders of glycosylation [68]. Mostly, dominant acting, 
de novo mutations have been identified in children suffering 
from DEEs [32], and only a limited number of genes with 
a recessive mode of inheritance are known so far, with a 
higher occurrence rate in consanguineous populations [71]. 
A recent cohort study on DEEs employing whole exome 
sequencing (WES) and copy number analysis, however, 
found that up to 38% of diagnosed cases might be caused by 
recessive genes, indicating that the importance of this mode 
of inheritance in DEEs has been underestimated [74].
The human genome contains ~ 20,000 genes of which 
more than 5000 have been implicated in genetic disorders. 
Wide-scale population genomic studies and CRISPR–Cas9-
based loss-of-function (LoF) screens have identified around 
3000–7000 genes that are essential for the viability of the 
human organism or result in profound loss of fitness when 
mutated, in agreement with that they are depleted for LoF 
variants in the human population [10]. For some of these 
essential genes, it is believed that LoF variants are incom-
patible with life and are, therefore, unlikely to be impli-
cated in genetic disorders presenting in postnatal life [84]. 
One such example is the UDP-glucose pyrophosphorylase 
(UGP2) gene at chromosome 2. UGP2 is an essential octa-
meric enzyme in nucleotide sugar metabolism [38, 39, 121], 
as it is the only known enzyme capable of catalyzing the 
conversion of glucose-1-phosphate to UDP-glucose [36, 
108]. UDP-glucose is a crucial precursor for the produc-
tion of glycogen by glycogen synthase (GYS) [2, 44], and 
also serves as a substrate for UDP-glucose:glycoprotein 
transferases (UGGT) and UDP-glucose-6-dehydrogenase 
(UGDH), thereby playing important roles in glycoprotein 
folding control, glycoconjugation and UDP-glucuronic acid 
synthesis. The latter is an obligate precursor for the synthesis 
of glycosaminoglycans and proteoglycans of the extracellu-
lar matrix [65, 110], of which aberrations have been associ-
ated with DEEs and neurological disorders [4, 24, 77, 98]. 
UGP2 has previously been identified as a marker protein in 
various types of malignancies including gliomas where its 
upregulation is correlated with a poor disease outcome [27, 
59, 61, 101, 103, 111, 112, 122], but has so far not been 
implicated in genetic diseases and it has been speculated that 
this is given its essential role in metabolism [38].
Many genes are differentially expressed amongst tis-
sues, regulated by non-coding regulatory elements [76]. 
In addition, it has become clear that there are more than 
40,000 protein isoforms encoded in the human genome, 
whose expression levels vary amongst tissues. Although 
there are examples of genetic disorders caused by the loss 
of tissue-specific protein isoforms [41, 47, 57, 100], it is 
unknown whether a tissue-relevant loss of an essential gene 
can be involved in human disease. Here, we report on such 
a scenario, providing evidence that a novel form of a severe 
DEE syndrome is caused by the brain-relevant loss of the 
essential gene UGP2 due to an isoform-specific and germ 
line-transmitted start codon mutation. We present data that 
this is likely a more frequent disease mechanism in human 
genetics, illustrating that essential genes for which organ-
ism-wide loss is lethal can still be implicated in genetic dis-
ease when only absent in certain tissues due to expression 
misregulation.
Methods
Patient recruitment
All affected probands were investigated by their referring 
physicians and all genetic analyses were performed in a 
diagnostic setting. Legal guardians of affected probands gave 
informed consent for genomic investigations and publication 
of their anonymized data.
Next‑generation sequencing of index patients
Individual 1
Genomic DNA was isolated from peripheral blood leuko-
cytes of the proband and both parents, and exome-coding 
DNA was captured with the Agilent SureSelect Clinical 
Research Exome (CRE) kit (v2). Sequencing was per-
formed on an Illumina HiSeq 4000 with 150-bp paired-end 
reads. Reads were aligned to hg19 using BWA (BWA-MEM 
v0.7.13) and variants were called using the GATK haplotype 
caller (v3.7 (reference: https ://www.broad insti tute.org/gatk/) 
[67]. Detected variants were annotated, filtered and prior-
itized using the Bench lab NGS v5.0.2 platform (Agilent 
technologies). Initially, only genes known to be involved in 
epilepsy were analyzed, followed by a full exome analysis 
revealing the homozygous UGP2 variant.
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Individuals 2, 3 and 4
Using genomic DNA from the proband and parents (individ-
ual 4) or the proband, parents, and affected sibling (individu-
als 2 and 3), the exonic regions and flanking splice junctions 
of the genome were captured using the SureSelect Human 
All Exon V4 (50 Mb) (individual 4) or the IDT xGen Exome 
Research Panel v1.0 (individuals 2 and 3). Massively par-
allel (NextGen) sequencing was done on an Illumina sys-
tem with 100 bp or greater paired-end reads. Reads were 
aligned to human genome build GRCh37/UCSC hg19 and 
analyzed for sequence variants using a custom-developed 
analysis tool. Additional sequencing technology and variant 
interpretation protocol has been previously described [82]. 
The general assertion criteria for variant classification are 
publicly available on the GeneDx ClinVar submission page 
(https ://www.ncbi.nlm.nih.gov/clinv ar/submi tters /26957 /).
Individual 5
Diagnostic exome sequencing was done at the Departments 
of Human Genetics of the Radboud University Medical 
Center Nijmegen, The Netherlands, and performed essen-
tially as described previously [96].
Individuals 6, 7, 8, 9, 10, 14, 15, 16, 17 and 18
After informed consent, we collected blood samples from 
the probands, their parents and unaffected siblings, and 
extracted DNA using standard procedures. To investigate 
the genetic cause of the disease, WES was performed in 
the affected proband. Nextera Rapid Capture Enrichment kit 
(Illumina) was used according to the manufacturer’s instruc-
tions. Libraries were sequenced in an Illumina HiSeq3000 
using a 100-bp paired-end reads protocol. Sequence align-
ment to the human reference genome (UCSC hg19), vari-
ants calling, and annotation were performed as described 
elsewhere [69]. After removing all synonymous changes, 
we filtered single nucleotide variants (SNVs) and indels, 
only considering exonic and donor/acceptor splicing vari-
ants. In accordance with the pedigree and phenotype, pri-
ority was given to rare variants [< 1% in public databases, 
including 1000 Genomes project, NHLBI Exome Variant 
Server, Complete Genomics 69, and Exome Aggregation 
Consortium (ExAC v0.2)] that were fitting a recessive or a 
de novo model. After identifying the UGP2 variant in the 
proband, Sanger sequencing was used to confirm segregation 
in other affected and unaffected family members.
Individuals 11, 20, 21 and 22
Whole exome sequencing was performed at CENTOGENE 
AG, as previously described [105].
Individuals 12 and 13
High-quality DNA was used to capture exons using the Sure-
Select kit (Agilent, Santa Clara, CA, US). Then genomic 
libraries were created according to the manufacturer’s pro-
tocols. Sequences were read on Proton (Life Technologies 
Inc., Carlsbad, CA, US). Downstream analyses such as 
sequence alignment, indexing and raw variant calling were 
done using publicly and commercially available tools such 
as Ion Reporter, SAMTools, and Genomic Analysis ToolKit. 
Moreover, variant interrogations were done using sequence-
variant databases, such as dbSNP, Ensembl, and the National 
Heart, Lung, and Blood Institute (NHLBI) Exome Variant 
Server (EVS), 1000 genome project.
Individual 19
Whole exome sequencing was performed in a diagnos-
tic setting at MEDGENOME, India. DNA extracted from 
blood was used to perform targeted gene capture using the 
Agilent SureSelect V5 exome capture kit. The libraries 
were sequenced to mean > 80–100 × coverage on Illumina 
sequencing platform. GATK best practices framework was 
used for variant identification using Sentieon (v201808.01), 
sequences obtained were aligned to GRCh37/hg19 using 
Sentieon aligner and analyzed using Sentieon for removing 
duplicates, recalibration and re-alignment of indels. Sentieon 
haplotypecaller has been used to identify variants which are 
relevant to the clinical indication. Gene annotation of the 
variants was performed using VEP program against the 
Ensemble release 91 human gene model.
Human brain samples
Tissue was obtained, upon informed consent, and used in a 
manner compliant with the Declaration of Helsinki and the 
Research Code provided by the local ethical committees. 
Fetal brains were preserved after spontaneous or induced 
abortions with appropriate written consent for brain autopsy 
and use of rest material for research. We performed a careful 
histological and immunohistochemical analysis, and evalua-
tion of clinical data (including genetic data, when available). 
We only included specimens displaying a normal cortical 
structure for the corresponding age and without any signifi-
cant brain pathology.
Brain tissue immunohistochemistry
For immunohistochemical analysis, we used two cases 
from the first trimester (GW6 and GW9), four cases from 
the second trimester (GW21, GW23, GW24 and GW26) 
and two cases from the third trimester (GW33 and GW36). 
Anatomical regions were determined according to the 
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atlas of human brain development [11–14]. We cut 4-µm 
sections from formalin-fixed, paraffin-embedded whole 
fetuses (GW6 and GW9) and brain tissue from cerebral, 
mesencephalic, cerebellar and brain stem regions (from 
GW21 to GW36). Slides were stained with mouse anti-
UGP2 (C-6) in a 1:150 dilution (Santa Cruz) and visual-
ized using Mouse and Rabbit Specific HRP/DAB (ABC) 
Detection IHC kit (Abcam). Mayer’s hematoxylin was 
used as a counterstain for immunohistochemistry fol-
lowed by mounting and coverslipping (Bio-Optica) for 
slides. Prepared slides were analyzed and scanned under 
a  VisionTek® Live Digital Microscope (Sakura).
Cloning of UGP2 cDNA
RNA was isolated using TRI reagent (Sigma) from whole 
peripheral blood of index patient 1 and her parents, after 
red blood cell depletion with RBC lysis buffer (168 mM 
 NH4Cl, 10 mM  KHCO3, 0.1 mM EDTA). cDNA was syn-
thesized following the iSCRIPT cDNA Synthesis Kit (Bio-
Rad) protocol, and the coding sequence of the long and 
short UGP2 isoform (wild type or mutant) was PCR ampli-
fied together with homology arms for Gibson assembly 
(see Supplementary Table 8, online resource, for primer 
sequences) using Phusion High-Fidelity DNA polymerase 
(NEB). PCR-amplified DNA was then cloned by Gibson 
assembly as previously described [9] in a pPyCAG-IRES-
puro plasmid (a kind gift from Ian Chambers, Edinburgh) 
opened with EcoRI for experiments in mammalian cells. 
All obtained plasmids were sequence verified by Sanger 
sequencing (complete plasmid sequences available upon 
request).
Fibroblast cell culture
Fibroblasts from index patient 1 and her parents were 
obtained using a punch biopsy according to standard 
procedures, upon informed consent (IRB approval MEC-
2017-341). Fibroblasts from the parents of index patients 
2 and 3 were also obtained upon informed consent at 
McMaster Children’s Hospital. All fibroblasts were cul-
tured in standard DMEM medium supplemented with 15% 
fetal calf serum, MEM non-essential amino acids (Sigma), 
100 U/ml penicillin and 100 µg/ml streptomycin, as done 
previously [6], in routine humidified cell culture incuba-
tors at 20%  O2. Fibroblast cell lines were transfected using 
Lipofectamine 3000 (Invitrogen) with the indicated plas-
mid constructs. All cell lines used in this report were regu-
larly checked for the presence of mycoplasma and were 
negative during all experiments.
Genome engineering in human embryonic stem 
cells
H9 human embryonic stem cells were cultured as previ-
ously described [8, 9]. In short, cells were maintained on 
feeder-free conditions in mTeSR-1 medium (STEMCELL 
technologies) on Matrigel (Corning)-coated culture dishes. 
To engineer the patient-specific UGP2 mutation by homolo-
gous recombination [7], ESCs were transfected using Lipo-
fectamine 3000 with a plasmid expressing eSpCas9-t2a-GFP 
(a kind gift of Feng Zhang) and a gRNA targeting the UGP2 
gene (see Supplementary Table 8, online resource, for the 
sequence), together with a 60-bp single-stranded oligonu-
cleotide (ssODN) homology template encoding the patient 
mutation (synthesized at IDT). To increase the stability of 
the ssODN and, therefore, homologous recombination effi-
ciency, the first two 5′ and 3′ nucleotides were synthesized 
using phosphorothiorate bonds [80]. 48 h post-transfection, 
GFP-expressing cells were sorted, and 6000 single GFP-pos-
itive cells were plated on a Matrigel-coated six-well plate in 
the presence of 10 µM ROCK-inhibitor (Y27632, Millipore). 
After approximately 10 days, single colonies where manu-
ally picked, expanded and genotyped using Sanger sequenc-
ing (see Supplementary Table 8, online resource, for primer 
sequences). As a by-product of non-homologous end join-
ing, knockout clones were obtained which showed a single 
nucleotide A insertion at position 42 of UGP2 transcript 
1 (chr2:64083462_64083463insA), leading to an out-of-
frame transcript and a premature termination of the protein 
at amino acid position 47 (D15Rfs*33). Western blotting 
confirmed the absence of all UGP2 proteins in knockout 
clones and the loss of the short UGP2 isoform in clones 
with the patient mutation. To produce a stable rescue cell 
line, ESCs were transfected as previously described with 
the pPyCAG-IRES-puro plasmid expressing either the long 
WT or mutant UGP2 isoform. After 48 h, the population of 
cells with the transgene integration was selected with 1 µg/
ml puromycin. Engineered ESC clones had a normal colony 
morphology and pluripotency factor expression.
Patient‑specific induced pluripotent stem cell 
generation
Patient fibroblast cell lines were reprogrammed using the 
CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Thermo 
Scientific, A16517) expressing the reprogramming fac-
tors OCT4, SOX2, KLF4 and C-MYC on Matrigel-coated 
cell culture plates, upon informed consent (IRB approval 
MEC-2017–341). After approximately 4–5 weeks, emerg-
ing colonies were manually picked and expanded. Multi-
ple clones were assessed for their karyotype, pluripotency 
factor expression and three lineage differentiation potential 
(Stem Cell Technologies, #05230), following the routine 
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procedures of the Erasmus MC iPS Cell core facility, as pre-
viously described [6]. Sanger sequencing was used to verify 
the genotype of each obtained iPSC line. We used three vali-
dated clones for each individual in our experiments.
Neural stem cell differentiation
Pluripotent cells were differentiated in neural stem cells 
(NSCs), using a modified dual SMAD inhibition protocol 
[20]. In short, 18,000 cells/cm2 were plated on Matrigel-
coated cell culture dishes in mTeSR-1 medium in the pres-
ence of 10 µM Y27632. When cells reached 90% confluency, 
the medium was switched to differentiation medium (Knock-
Out DMEM (Gibco), 15% KnockOut serum replacement 
(Gibco), 2 mM l-glutamine (Gibco), MEM non-essential 
amino acids (Sigma), 0.1 mM β-mercaptoethanol, 100U/ml 
penicillin and 100 µg/ml streptomycin) supplemented with 
2 µM A 83-01 (Tocris) and 2 µM Dorsomorphin (Sigma-
Aldrich). At day 6, medium was changed to an equal ratio 
of differentiation medium and NSC medium (KnockOut 
DMEM-F12 (Gibco), 2 mM l-glutamine (Gibco), 20 ng/ml 
bFGF (Peprotech), 20 ng/ml EGF (Peprotech), 2% StemPro 
Neural supplement (Gibco), 100U/ml penicillin and 100 µg/
ml streptomycin) supplemented with 2 µM A 83-01 (Toc-
ris) and 2 µM Dorsomorphin (Sigma-Aldrich). At day 10, 
cells were passaged (NSC p = 0) using Accutase (Sigma) and 
maintained in NSC medium. We used commercially avail-
able H9-derived NSCs (Gibco) as a control (a kind gift from 
Raymond Poot, Rotterdam).
Other stem cell differentiation experiments
ESCs were differentiated into hematopoietic stem cells and 
cardiomyocytes using commercially available STEMCELL 
technology kits (STEMdiff Hematopoietic kit #05310, 
STEMdiff Cardiomyocyte differentiation kit #05010) 
according to the manufacturer’s instructions. Cells were 
finally harvested and lysed with TRI reagent to isolate RNA 
for further qRT-PCR analysis.
RNA‑sequencing and data analysis
For patient RNA-seq, peripheral blood was obtained from 
index patient 1 and her parents, collected in PAX tubes and 
RNA was isolated following standard diagnostic procedures 
in the diagnostics unit of the Erasmus MC Clinical Genet-
ics department. RNA-seq occurred in a diagnostic setting, 
and sequencing was performed at GenomeScan (Leiden, The 
Netherlands). For RNA-seq of in vitro-cultured cell lines, 
RNA was obtained from six-well cultures using TRI rea-
gent, and further purified using column purification (Qiagen, 
#74204). mRNA capture, library prep including barcoding 
and sequencing on an Illumina HiSeq2500 machine were 
performed according to standard procedures of the Eras-
mus MC Biomics facility. Approximately 20 million reads 
were obtained per sample. For cell line experiments, two 
independent H9 wild-type cultures, two independent knock-
out clones harboring the same homozygous UGP2 genetic 
alteration and two independent clones harboring the patient 
homozygous UGP2 mutation were used. Each cell line was 
sequenced in two technical replicates at ESC state and dif-
ferentiated NSC state (at passage 5). FASTQ files obtained 
after de-multiplexing of single-end, 50-bp sequencing reads 
were trimmed by removing possible adapters using Cutadapt 
after quality control checks on raw data using the FastQC 
tool. Trimmed reads were aligned to the human genome 
(hg38) using the HISAT2 aligner [50]. To produce Genome 
Browser Tracks, aligned reads were converted to bedgraph 
using bedtools genomecov, after which the bedGraphToBig-
Wig tool from the UCSC Genome Browser was used to cre-
ate a bigwig file. Aligned reads were counted for each gene 
using htseq-count [3] and GenomicFeatures [55] was used 
to determine the gene length by merging all non-overlap-
ping exons per gene from the Homo_sapiens.GRCh38.92.
gtf file (Ensemble). Differential gene expression and RPKM 
(Reads Per Kilobase per Million) values were calculated 
using edgeR [85] after removing low-expressed genes and 
normalizing data. The threshold for significant differences in 
gene expression was FDR < 0.05. To obtain a list of ESC and 
NSC reference genes used in Supplementary Fig. 6F, online 
resource, we retrieved genes annotated in the following GO 
terms using GSEA/MSigDB web site v7.0: GO_FORE-
BRAIN_NEURON_DEVELOPMENT (GO:0021884), GO_
CEREBRAL_CORTEX_DEVELOPMENT (GO:0021987), 
GO_NEURAL_TUBE_DEVELOPMENT (GO:0021915), 
BHATTACHARYA_EMBRYONIC_STEM_CELL (PMID: 
15070671) and BENPORATH_NOS_TARGETS (PMID: 
18443585).
Functional enrichment analysis
Metascape [123], g:profiler [79] and Enrichr [52] were used 
to assess functional enrichment of differentially expressed 
genes. Supplementary Table 4, online resource, reports all 
outputs in LogP, log(q value) and Adjusted p value (q value) 
for Metascape and g:profiler, and in p value, Adjusted p 
value (q value) and combined score (which is the estimation 
of significance based on the combination of Fisher’s exact 
test p value and z score deviation from the expected rank) 
for Enrichr. All tools were used with default parameters and 
whole genome set as background.
Genome‑wide homology search
To make a genome-wide list of transcripts sharing a simi-
lar structure as UGP2 transcripts, 42,976 transcripts from 
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21,522 genes (Human genes GRCh38.p12) were extracted 
using BioMart of Ensembl (biomaRt R package). 11,056 
out of 21,522 genes had only 1 transcript and the remaining 
31,920 transcripts from 10,466 genes were selected, the pro-
tein sequences were obtained with biomaRt R package and 
homology analysis was performed using the NCBI’s blastp 
(formatting option: -outfmt = 6) command line. We grouped 
longest and shorter transcript based on coding sequence 
length and only kept those that matched a pairwise homol-
ogy comparison between the longest and the shorter tran-
script with the following criteria: complete 100 percent iden-
tity, without any gap and mismatch, and starting ATG codon 
of shortest transcript being part of the longest transcript(s). 
1766 genes meet these criteria. We then filtered these genes 
for published essential genes [10], leaving us with 1197 
genes. Using BioMart (Attributes: Phenotype description 
and Study external reference) of Ensembl we then evaluated 
the probability that these genes were implicated in disease 
and identified 850 genes that did not have an association 
with disease phenotype/OMIM number. Of those, 247 genes 
encoded proteins of which the shorter isoform differed less 
than 50 amino acids from the longer isoform. We chose this 
arbitrary threshold to exclude those genes where both iso-
forms could encode proteins differing largely in size and 
might, therefore, encode functionally completely differing 
proteins (although we cannot exclude that this will also hold 
true for some of the genes in our selection).
Differential isoform expression in fetal tissues
Publically available RNA-seq data from various fetal tis-
sue samples (Supplementary Table 2, online resource) were 
analyzed using the same workflow as described for the RNA-
seq data analysis above. To determine differential isoform 
expression in these tissues, we calculated a ratio between 
the unique exon(s) of the shortest and longest transcript for 
each gene and assessed its variability across different fetal 
tissue samples. The number of reads for each unique exon 
of a transcript was calculated by mapping aligned RNA-
seq reads against the unique exon coordinate using bedtools 
multicov. The longest and shortest transcripts were separated 
and the transcript ratio (number of counts of shortest tran-
script/(number of counts of shortest transcript + number of 
counts of longest transcript)) for each gene was obtained 
from the average reads of RNA-seq samples per tissue. 382 
genes out of 1197 genes showed high variability across dif-
ferent samples (defined as a difference between highest and 
lowest ratio > 0.5), 277 of those highly variable genes were 
not associated with a disease phenotype/OMIM number and 
of these 83 genes had a length less than 50 amino acids (a 
subset of the 247 genes with no OMIM and length less than 
50 amino acids).
Haplotype analysis
The 30 MB region surrounding UGP2 was extracted from 
exome sequencing VCF files to include both common and 
rare polymorphisms. Variants were filtered for a minimum 
depth of coverage of at least 10 reads and a genotype quality 
of at least 50. The filtered variants were then used as input 
in PLINK (v1.07) with the following settings:
• homozyg-snp 5
• homozyg-kb 100
• homozyg-gap 10,000
• homozyg-window-het 0
ROH around the UGP2 variant was identified in all 
five probands examined. The minimum ROH in com-
mon between all samples was a 5-Mb region at chr2: 
60679942–65667235. We note that targeted sequencing 
leads to uneven SNP density, so the shared ROH may, in 
fact, be larger or smaller. Next, we used recombination maps 
from deCODE to estimate the size of the region in centiMor-
gans (cM). We then used the region size in cM to estimate 
the time to event in generations using methods previously 
described [120].
qPCR analysis
RNA was obtained using TRI reagent, and cDNA prepared 
using iSCRIPT cDNA Synthesis Kit according to the man-
ufacturer’s instructions. qPCR was performed using iTaq 
universal SYBR Green Supermix in a CFX96RTS thermal 
cycler (Bio-Rad). Supplementary Table 8, online resource, 
summarizes all primers used in this study. Relative gene 
expression was determined following the ΔΔct method. To 
calculate the ratio of the short isoform, we performed abso-
lute quantification as previously described [109]. Briefly, 
we performed qPCR on known copy numbers, ranging from 
 103 to  108 copies, of a plasmid containing the short UGP2 
isoform (5′ UTR included) using primers detecting specifi-
cally either the total or the short isoform. After plotting the 
log copy number versus the ct, we obtained a standard curve 
that we used to extrapolate the copy number of the unknown 
samples. To test for significance, we used Student’s T test 
and considered p < 0.05 as significant.
Western blotting
Proteins were extracted with NE buffer (20 mM HEPES, 
pH 7.6, 1.5 mM  MgCl2, 350 mM KCl, 0.2 mM EDTA and 
20% glycerol) supplemented with 0.5% NP40, 0.5 mM DTT, 
cOmplete Protease Inhibitor Cocktail (Roche) and 150 U/
ml benzonase. Protein concentration was determined by 
BCA (Pierce) and 20–50 µg of proteins was loaded onto 
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a 4–15% Criterion TGX gel (Bio-Rad). Proteins were then 
transferred to a nitrocellulose membrane using the Trans-
Blot Turbo Transfer System (Bio-Rad). The membrane was 
blocked in 5% milk in PBST and subsequently incubated 
overnight at 4 °C with primary antibody diluted in milk. 
After PBST washes, the membrane was incubated 1 h at 
RT with the secondary antibody and imaged with an Odys-
sey CLX scanning system (Li-Cor). Band intensities were 
quantified using Image Studio (Li-cor). Antibodies used 
were Ms-α-UGP2 (sc-514174) 1:250; Ms-α-Vinculin (sc-
59803) 1:10,000; Gt-α-actin (sc-1616) 1:500; Ms-α-LAMP2 
(H4B4) 1:200; IRDye 800CW Goat anti-Mouse (926-32210) 
1:5000; IRDye 680 Donkey anti-Goat (926-32224) 1:5000.
Zebrafish disease modeling
Animal experiments were approved by the Animal Experi-
mentation Committee at Erasmus MC, Rotterdam. Zebrafish 
embryos and larvae were kept at 28  °C on a 14–10‐h 
light–dark cycle in 1  M HEPES buffered (pH 7.2) E3 
medium (34.8 g NaCl, 1.6 g KCl, 5.8 g  CaCl2·2H2O, 9.78 g 
 MgCl2·6H2O). For live imaging, the medium was changed 
at 1 dpf to E3 + 0.003% 1‐phenyl 2‐thiourea (PTU) to pre-
vent pigmentation. Ugp2a and ugp2b were targeted by Cas9/
gRNA RNP complex as we did before [51]. Briefly, fertilized 
oocytes from a tgBAC(slc1a2b:Citrine)re01tg reporter line 
[51] maintained on an TL background strain were obtained, 
and injected with Cas9 protein and crRNA and tracrRNA 
synthesized by IDT (Alt-R CRISPR–Cas9 System), target-
ing the open reading frame of zebrafish ugp2a and ugp2b. 
DNA was extracted from fin clips and used for genotyping 
using primers flanking the gRNA location (Supplementary 
Table 8, online resource) followed by sequencing. Mutants 
with a high level of out-of-frame indels in both genes were 
identified using TIDE [18] and intercrossed to obtain germ 
line transmission. Upon re-genotyping, mutant zebrafish 
with the following mutations as indicated in Fig. 6 were 
selected and further intercrossed. In this study, we describe 
two new mutant fish lines containing deletions in ugp2a 
(ugp2aΔ/Δ) and ugp2b (ugp2bΔ/Δ): ugp2are08/re08 contain-
ing a 37 bp deletion in exon 2 and ugp2bre09/re09 containing 
a 5 bp deletion in exon 2. Intravital imaging, and analysis 
of eye movement, was performed as previously described 
[51]. Briefly, zebrafish larvae anesthetized in tricaine were 
mounted in low-melting point agarose-containing tricaine 
and imaged using a Leica SP5 intravital imaging setup with 
a 20 × /1.0 NA water-dipping lens. To assess the locomo-
tor activity of zebrafish larvae from 3 to 5 dpf, locomotor 
activity assays were performed using an infrared camera 
system (DanioVision™ Observation chamber, Noldus) 
and using  EthoVision® XT software (Noldus) as described 
[51]. Briefly, control (n = 24) and ugp2aΔ/Δ; ugp2bΔ/Δ 
(n = 24) zebrafish larvae, in 48-well plates, were subjected 
to gradually increasing (to bright light) and decreasing light 
conditions (darkness) as in Kuil et al. [51]. Distance traveled 
(mm) per second was measured. For 4-AP (Sigma) stimula-
tion, animals were treated with 4-AP dissolved in DMSO 
30 min before the onset of the experiments. For these experi-
ments, locomotor activity was measured over 35 min, with 
the first 5 min going from dark to light, followed by 30 min 
under constant light exposure.
Periodic acid–Schiff (PAS) staining
ESCs or differentiated NSCs (wild type, KO, KI or rescue) 
were incubated under hypoxia conditions (3%  O2) for 48 h. 
Cells were fixed with 5.2% formaldehyde in ethanol, incu-
bated 10 min with 1% periodic acid, 15 min at 37 °C with 
Schiff’s reagent (Merck) and 5 min with hematoxylin solu-
tion (Klinipath) prior to air drying and mounting. Every step 
of the protocol is followed by a 10-min wash with tap water. 
Imaging occurred on an Olympus BX40 microscope. Images 
were acquired at a 100 × magnification, and ImageJ software 
was used for quantification. For ESCs, we used a minimum 
of 20 images per genotype for the quantification, contain-
ing on average 20 cells each, calculating the percentage of 
PAS-positive area. For NSCs, we imaged between 80 and 
100 cells per genotype, counting the number of glycogen 
granules in the cytoplasm. We report the average of two 
independent experiments at 48 h low oxygen.
UGP2 enzymatic activity
The measurement of UGP2 enzyme activity was performed 
according to a modified GALT enzyme activity assay as 
described previously [62]. Frozen cell pellets were defrosted 
and homogenized on ice. 10 µl of each cell homogenate 
(around 0.5 mg protein/ml as established by BSA protein 
concentration determination) was pre-incubated with 10 µl 
of dithiothreitol (DDT) for 5 min at 25 °C. 80 µl of a mixture 
of glucose-1-phosphate (final concentration 1 mM), UTP 
(0.2 mM), magnesium chloride (1 mM), glycine (125 mM) 
and Tris–HCl (pH8) (40 mM) was added and incubated for 
another 15 min at 25 °C. The reaction was stopped by add-
ing 150 µl of 3.3% perchloric acid. After 10 min on ice, the 
mixture was centrifuged (10,000 rpm for 5 min at 4 °C), 
the supernatant isolated and neutralized with ice-cold 8 µl 
potassium carbonate for 10 min on ice. After centrifugation, 
the supernatant was isolated and 1:1 diluted with eluent B 
(see below) after which the mixture was added to a Milli-
Pore Amicon centrifugal filter unit. After centrifugation, the 
supernatant was stored at − 20 °C until use. The separation 
was performed by injection of 10 µl of the defrosted super-
natant onto a HPLC system with UV/VIS detector (wave-
length 262 nm) equipped with a reversed-phase Supelcosil 
LC-18-S 150 mm × 4.6 mm, particle size 5 µm, analytical 
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column and Supelguard LC18S guard column (Sigma-
Aldrich). During the experiments, the temperature of the 
column was maintained at 25 °C. The mobile phase con-
sisted of eluent A (100% methanol) and eluent B (50 mM 
ammonium phosphate buffer pH 7.0 and 4 mM tetrabutylam-
monium bisulphate). A gradient of 99% eluent B (0–20 min), 
75% eluent B (20–30 min) and 99% eluent B (30–45 min) 
at a flow rate of 0.5 m/min was used. The reaction product 
UDP-glucose was quantified using a calibration curve with 
known concentrations of UDP-glucose. UGP2 activity was 
expressed as the amount of UDP-glucose formed per mg 
protein per min. Experiments were performed in duplicate 
and for every cell line two independently grown cell pellets 
were used.
Immunostaining/immunohistochemistry
For immunofluorescence staining, cells were seeded on cov-
erslips coated with 100 µg/ml poly-d-lysine (Sigma) over-
night. For ESC, coverslips were further coated with Matrigel 
(Corning) for 1 h at 37 °C. At 70% confluency, cells were 
fixed with 4% PFA for 15 min at RT. Cells were then per-
meabilized with 0.5% Triton in PBS, incubated 1 h in block-
ing solution (3% BSA in PBS) and then overnight at 4 °C 
with the primary antibody diluted in blocking solution. The 
next day coverslips were incubated 1 h at room temperature 
in the dark with a Cy3-conjugated secondary antibody and 
mounted using ProLong Gold antifade reagent with DAPI 
(Invitrogen) to counterstain the nuclei. Images were acquired 
with a ZEISS Axio Imager M2 using a 63X objective.
Data availability
RNA-Seq of in vitro studies is publicly available through 
the National Center for Biotechnology Information (NCBI) 
Gene Expression Omnibus (GEO) under accession number 
GSE137129. Due to privacy regulations and consent, raw 
RNA-seq data from patient blood and genomic sequenc-
ing data cannot be made available. To retrieve tissue wide 
expression levels of UGP2, the GTEx Portal was accessed 
on 16/07/2019 (https ://gtexp ortal .org/home/). RNA-seq data 
from various tissues were downloaded from various publi-
cations [46, 83, 94, 118]. All publically available data that 
were re-analyzed here are summarized in Supplementary 
Table 2, online resource.
Results
A recurrent ATG mutation in UGP2 in 22 individuals 
presenting with a severe DEE
We encountered a 3-month-old girl (Fig. 1a, family 1, indi-
vidual 1) that was born as the first child to healthy non-
consanguineous Dutch parents, by normal vaginal deliv-
ery after an uneventful pregnancy conceived by ICSI. She 
presented in the first weeks of life with irritability and jit-
teriness, which developed into infantile spasms and severe 
epileptic activity on multiple electroencephalograms, giv-
ing rise to a clinical diagnosis of West syndrome (Fig. 1b). 
Despite the use of multiple anti-epileptic drugs, including 
ACTH and a ketogenic diet, seizures remained intractable 
and occurred daily. Severe developmental delay was evi-
dent without acquisition of any noticeable developmental 
milestones, causing the need for gastrointestinal tube feed-
ing. Visual tracking was absent, and foveal hypopigmenta-
tion, hypermetropia and mild nystagmus were noticed upon 
ophthalmological investigation. MRI brain imaging showed 
no gross structural abnormalities or migration disorders at 
the age of 4 months, but displayed reduced white matter, 
that further developed into global atrophy with wide sulci 
and wide pericerebral liquor spaces at the age of 17 months 
(Fig. 1c, Supplementary Fig. 1b, online resource). At that 
time, she had become progressively microcephalic, with 
a head circumference of − 2.96 SD at the last investiga-
tion at 23 months of age (Supplementary Fig. 1a, online 
resource). She showed a number of minor dysmorphisms, 
including a sloping forehead, elongated head with suture 
ridging, bitemporal narrowing, a relatively small mouth and 
large ears (Fig. 1a). Neurological examination showed brisk, 
Fig. 1  UGP2 homozygous variants in 20 individuals with severe epi-
leptic encephalopathy. a Facial pictures of individual 1 (at 18 and 
23  months), individual 5 (at 9  years), individual 6 (at 11  months), 
individual 9 (at 18  months), individual 10 (at 2  years) and individ-
ual 19 (at 13 months). Note the progressive microcephaly with slop-
ing forehead, suture ridging, bitemporal narrowing, high hairline, 
arched eyebrows, pronounced philtrum, a relatively small mouth 
and large ears. b Electroencephalogram of individual 1 at the age of 
8  months showing a highly disorganized pattern with high-voltage 
irregular slow waves intermixed with multifocal spikes and poly-
spikes. c T1-weighted mid-sagittal brain MRI of individual 1 (at 
17 months) and individual 4 (at 24 months) illustrating global atro-
phy and microcephaly but no major structural anomalies. d Sanger 
sequencing traces of family 1, confirming the chr2:64083454A>G 
variant in UGP2 in heterozygous and homozygous states in parents 
and affected individual 1, respectively. e Family pedigrees of ascer-
tained patients. Affected individuals and heterozygous parents are 
indicated in black and half black, respectively. Affected individuals 
with confirmed genotype are indicated with an arrow, and numbers. 
Other not-tested  affected siblings presenting with similar phenotypes 
are indicated with a question mark. Consanguineous parents are indi-
cated with a double connection line. Males are squares, females are 
circles; unknown sex is indicated with rotated squares; deceased indi-
viduals are marked with a line. f Violin plots showing distribution of 
gene expression (in TPM) amongst male and female samples from 
the GTEx portal for various brain regions. Outliers are indicated by 
dots. g Multiple species sequence alignment from the UCSC browser, 
showing that the ATG start site is highly conserved
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symmetric deep tendon reflexes, more pronounced at the 
upper limbs. Routine investigations, including metabolic 
screening in urine, plasma and cerebrospinal fluid were 
normal. A SNP-array showed a normal female chromo-
somal profile, with a large, ~ 30 Mb run of homozygosity 
(ROH) at chromosome 2, and a few smaller ROH regions, 
adding up to 50 Mb ROH regions in total, pointing to an 
unrecognized common ancestor of both parents (coefficient 
of inbreeding 1/64). Subsequent trio WES did not show any 
disease-causing variants in known DEE genes, but identi-
fied a homozygous variant (chr2:64083454A>G) in UGP2, 
located in the large ROH region (Fig. 1d), with no other 
disease-implicated variants observed in that region. Both 
parents were heterozygous carriers of the same variant. Via 
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Genematcher [97] and our network of collaborators, we 
identified 21 additional individuals from 14 unrelated fami-
lies (of which 10 were consanguineous), harboring the exact 
same homozygous variant and presenting with an almost 
identical clinical phenotype of intractable seizures, severe 
developmental delay, visual disturbance, microcephaly and 
similar minor dysmorphisms (Fig. 1a, c, e, Supplementary 
Fig. 1b, Supplementary Case reports, Supplementary Movie 
1, Supplementary Table 1, online resource, for detailed 
information on 18 cases). Ten of these individuals passed 
away early, with the majority before the age of 3.5 years. In 
six families, at least seven already deceased siblings had a 
similar phenotype but could not be investigated. Two fami-
lies were of Indian descent (both with ancestors from regions 
currently belonging to Pakistan), living in Canada (family 2) 
and the USA (family 3), with the remaining families from 
Oman (family 4, originally from Pakistan), Pakistan (family 
5, family 13), Iran (families 6, 7, 8 and 11), UAE (family 
9), Saudi Arabia (family 10) and India (family 12). Two 
additional cases in family 14 from Oman and family 15 from 
India were identified presenting with intractable seizures and 
microcephaly, but no detailed medical information could be 
obtained at this point.
Having identified at least 22 individuals with an almost 
identical clinical phenotype and an identical homozy-
gous variant in the same gene led us to pursue UGP2 as 
a candidate gene for a new genetic form of DEE. UGP2 
is highly expressed in various brain regions (Fig.  1f), 
and also widely expressed amongst other tissues, includ-
ing liver and muscle according to the data from the GTEx 
portal [23] (Supplementary Fig. 1d, online resource). The 
(chr2:64083454A>G) variant is predicted to cause a mis-
sense variant (c.34A>G, p.Met12Val) in UGP2 isoform 1 
(NM_006759), and to cause a translation start loss (c.1A>G, 
p.?.) of UGP2 isoform 2 (NM_001001521), referred to 
as long and short isoforms, respectively. The variant has 
not been reported in the Epi25 web browser [31], ClinVar 
[54], LOVD [37], Exome Variant Server [33], DECIPHER 
[35], GENESIS [40], GME variome [90] or Iranome data-
bases [34], is absent from our in-house data bases and is 
found only 15 times in a heterozygous, but not homozy-
gous, state in the 280,902 alleles present in gnomAD (MAF: 
0.00005340) [56]. In the GeneDx unaffected adult cohort, 
the variant was found heterozygous 10 times out of 173,502 
alleles (MAF: 0.00005764), in the ~ 10,000 exomes of the 
Queen Square Genomic Center database two heterozygous 
individuals were identified, and out of 45,921 individuals in 
the Centogene cohort, 10 individuals are heterozygous for 
this variant. The identified variant has a CADD score (v1.4) 
of 19.22 [81] and Mutation Taster [89] predicted this vari-
ant as disease causing. The nucleotide is strongly conserved 
over multiple species (Fig. 1 g). Analysis of WES data from 
5 patients did provide evidence of a shared ROH between 
patients from different families (including the Dutch family), 
indicating that this same variant might represent an ancient 
mutation that originated some 26 generations ago (Sup-
plementary Fig. 1c, online resource). Interestingly, since 
most families originally came from regions of India, Paki-
stan and Iran, overlapping with an area called Balochistan, 
this could indicate that the mutation has originated there 
around 600 years ago. As Dutch traders settled in that area 
in the seventeenth century, it is tempting to speculate that 
this could explain the co-occurrence of the variant in these 
distant places [1].
Short UGP2 isoform is predominantly expressed 
in brain and absent in patients with ATG mutations
Both UGP2 isoforms only differ by 11 amino acids at the 
N-terminal (Fig. 2a) and are expected to be functionally 
equivalent [38]. To investigate how the A>G variant may 
cause DEE, we first obtained fibroblasts from individual 1 
(homozygous for the A>G variant) and her heterozygous 
parents and analyzed the isoform expression by Western 
blotting (Fig. 2b). Whereas the two isoforms were equally 
expressed in wild-type fibroblasts, the expression of the 
shorter isoform was diminished to ~ 25% of total UGP2 
in heterozygous parents, both of individual 1 (Fig. 2b, 
c) and of individuals 2 and 3 (Supplementary Fig. 2a, b, 
online resource), and was absent in cells from the affected 
Fig. 2  UGP2 homozygous variant leads to a loss of the shorter pro-
tein isoform in patient fibroblasts. a Schematic drawing of the human 
UGP2 locus, with both long and short transcript isoforms. Boxes 
represent exons, with coding sequences indicated in green. The loca-
tion of the recurrent mutation is indicated in both transcripts. b West-
ern blotting of cellular extracts derived from control fibroblasts and 
fibroblasts obtained from family 1, detecting the housekeeping con-
trol vinculin and UGP2. Note the two separated isoforms of UGP2 
that have a similar intensity in wild-type cells. The shorter isoform 
is less expressed in fibroblasts from heterozygous parents and absent 
in fibroblasts from the affected proband. c Western blot quantifica-
tion of the fraction of short UGP2 protein isoform compared to total 
UGP2 expression in control, parental heterozygous and proband 
homozygous fibroblasts, as determined in three independent experi-
ments. Error bars represent SEM. d Western blot quantification of 
total UGP2 protein levels, as determined by the relative expression 
to the housekeeping control vinculin. Bar plot showing the results 
from three independent experiments. Error bars represent SEM; 
no significant differences were found between parents and proband, 
t test, two tailed. e Cell proliferation experiment of fibroblasts from 
heterozygous parents and homozygous proband from family 1, during 
a 5-day period, determined in three independent experiments. Error 
bars represent SEM. f Immunocytochemistry on cultured control and 
UGP2 heterozygous and homozygous mutant fibroblasts derived from 
family 1, detecting UGP2 (red). Nuclei are stained with DAPI. Scale 
bar 50 µm. g Enzymatic activity of UGP2 in control and UGP2 het-
erozygous and homozygous mutant fibroblasts derived from family 1. 
Shown is the mean of two independent experiments. Error bars repre-
sent SEM; no significant differences were found, unpaired t test, two 
tailed
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individual 1 (Fig. 2b, c; fibroblasts of the affected children 
in family 2 or other families were not available). Total 
UGP2 levels were not significantly different between the 
affected child and her parents, or between parents and 
wild-type controls (Fig. 2d, Supplementary Fig. 2c, online 
resource). This indicates that the long isoform harboring 
the Met12Val missense variant is upregulated in fibroblast 
when the short isoform is missing. Moreover, this indi-
cates that Met12Val does not affect the stability of the 
long isoform at the protein or transcript level (Supplemen-
tary Fig. 2d–f, online resource). RNA-seq on peripheral 
blood samples of family 1 did not identify altered splic-
ing events of UGP2 and the global transcriptome of the 
proband was not different from her parents, although only 
a limited analysis could be performed as only a single 
sample was available for each individual (Supplemen-
tary Fig. 2g, h, online resource). Both homozygous and 
heterozygous fibroblasts had a similar proliferation rate 
compared to wild-type fibroblasts (Fig. 2e, Supplemen-
tary Fig. 2i, online resource), and immunocytochemistry 
confirmed a similar subcellular localization of UGP2 in 
mutant and wild-type cells (Fig. 2f). We then measured 
the enzymatic activity of UGP2 in wild type, heterozygous 
and homozygous fibroblasts, and found that mutant fibro-
blast had a similar capacity to produce UDP-glucose in 
the presence of exogenously supplied glucose-1-phosphate 
and UTP (Fig. 2g). Altogether, this indicates that the long 
UGP2 isoform harboring the Met12Val missense change 
is functional and is, therefore, unlikely to contribute to the 
patient phenotype.
As the A>G variant results in a functional long UGP2 
isoform but abolishes the translation of the shorter UGP2 
isoform, we next investigated whether the ratio between 
short and long isoform differs amongst tissues. If so, the 
homozygous A>G variant would lead to depletion of UGP2 
in tissues where mainly the short isoform is expressed, pos-
sibly below a threshold that is required for normal devel-
opment or function. Western blotting on cellular extracts 
derived from wild-type H9 human embryonic stem cells 
(ESCs), commercially acquired H9-derived neural stem 
cells (NSCs) and fibroblasts (Fig. 3a) showed that, whereas 
the ratio between short and long isoform in fibroblasts was 
around 0.5, in ESCs it was 0.14 and in NSCs 0.77, indi-
cating that the shorter UGP2 isoform is the predominant 
one in NSCs (Fig. 3b). A similar trend was observed when 
assessing the transcript level, both by multiplex RT-PCR and 
qRT-PCR, using primers detecting specifically the short and 
long transcript isoform (Fig. 3c–e). This indicates that dif-
ferential isoform expression between cell types is regulated 
at the transcriptional level, possibly hinting at tissue-specific 
regulatory elements driving isoform expression. We next 
analyzed RNA-seq data from human fetal tissues [46, 83, 94, 
118] to determine the fraction of reads covering short versus 
total UGP2 transcripts (Fig. 3f). This showed that in human 
fetal brain the short transcript isoform is predominantly 
expressed. To gain more insight into the cell type-specific 
expression of UGP2, we performed immunohistochemistry 
on human fetal brain tissues from the first to third trimester 
of pregnancy (Fig. 3g). In the first trimester, we found pale 
labeling of neuropil in the proliferative neuroepithelium 
of the hypothalamic, cortical, mesencephalic and thalamic 
regions (Fig. 3g-A/I, II, III, IV), as well as the marginal zone 
of the spinal cord (Fig. 3g-A/V) and cuboidal epithelial cells 
of choroid plexus (Fig. 3g-A/VI). During the second trimes-
ter, UGP2 positivity was detected in neurons from the sub-
plate region of the cerebral cortex (Fig. 3g-B/I, II) and still 
in some of the cells in the neuroepithelium and subventricu-
lar zone (Fig. 3g-B/III). Almost the same pattern of UGP2 
distribution was found in the cerebral cortex of fetuses from 
the third trimester. Also, we found clear cytoplasmatic 
UGP2 expression in neurons from mesencephalic, inferior 
olivary and cerebellar nuclei during the second (Fig. 3g-B/
IV, V, and VI) and third trimester, respectively (Fig. 3g-C/
IV, V). In the white matter of the cerebellum in the third 
trimester, we identified single-positive glial cells (Fig. 3g-C/
VI). In the cerebellar cortex, we did not find specific positiv-
ity of cells on UGP2 (Fig. 3g-B, C/VII). Cuboidal epithelial 
cells of choroid plexus preserved UGP2 positivity during 
the second trimester (Fig. 3g-B/VIII) but lost it in the third 
trimester (Fig. 3g-C/VIII). Together this indicates that UGP2 
can be detected in a broad variety of cell types during brain 
development. On Western blotting, we noticed preferential 
expression of the shorter UGP2 isoform in the developing 
Fig. 3  UGP2 short isoform is predominant in brain-related cell types. 
a Western blotting showing UGP2 expression in H9 human embry-
onic stem cells (ESCs), H9-derived neural stem cells (NSCs) and 
fibroblasts (Fibro). Vinculin is used as a housekeeping control. Note 
the changes in relative expression between the two UGP2 isoforms 
in the different cell types. L, ladder. b Western blot quantification of 
the fraction of short UGP2 protein isoform compared to total UGP2 
expression, as determined in three independent experiments. Error 
bars represent SEM. c Multiplex RT-PCR of ESCs, NSCs and fibro-
blasts, showing a similar variability in isoform expression at the tran-
script and at the protein level. Each cell line was tested in triplicates. 
d Quantification of the fraction of the short UGP2 transcript isoform 
compared to total UGP2 expression, from the multiplex RT-PCR 
from c. Error bars represent SEM. e Quantification of the fraction of 
short UGP2 transcript isoform compared to total UGP2 expression 
by qRT-PCR in three independent experiments. Error bars represent 
SEM. f Ratio of RNA-seq reads covering the short transcript isoform 
compared to the total reads (covering both short and long isoforms), 
in multiple fetal tissues. In RNA-seq samples derived from brain, vir-
tually all UGP2 expressions come from the short isoform. Error bars 
represent SD. g Immunohistochemistry detecting UGP2 in human 
fetal brains from the first, second and third trimester (gestational 
week (GW) 6, 9, 23 and 36). See text for details. h Western blot-
ting detecting UGP2 in various human brain regions at weeks 14, 20 
and 28 of gestation, showing the virtual absence of the long isoform 
expression in fetal brain. Vinculin is used as a housekeeping control. 
L ladder
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cortex and cerebellum from gestational weeks 14, 20 and 28 
(Fig. 3h) and in the frontal cortex of brains from weeks 21 
and 23 (Supplementary Fig. 2j, online resource). Together, 
this supports the hypothesis that the DEE phenotype in 
patients is caused by a major loss of functional UGP2 in 
the brain, as the short isoform represents virtually all UGP2 
produced in this tissue.
Lack of the short UGP2 isoform leads 
to transcriptome changes upon differentiation 
into neural stem cells
To model the disease in  vitro, we first engineered the 
homozygous A>G mutation in H9 ESCs to study the muta-
tion in a patient independent genetic background and com-
pare it to isogenic parental cells. We obtained two independ-
ent clones harboring the homozygous A>G change (referred 
to as knock-in, KI, mutant) and two cell lines harboring an 
insertion of an additional A after nucleotide position 42 of 
UGP2 transcript 1 (chr2:64083462_64083463insA) (Sup-
plementary Fig. 3a, b, online resource) (referred to as knock-
out, KO). This causes a premature stop codon at amino acid 
position 47 (D15Rfs*33), leading to nonsense-mediated 
mRNA decay and complete absence of UGP2 protein (Sup-
plementary Fig. 3c, online resource). All derived ESCs had 
a normal morphology and remained pluripotent as assessed 
by marker expression (Supplementary Fig. 3d, e, online 
resource), indicating that the absence of UGP2 in ESCs is 
tolerated, in agreement with genome-wide LoF CRISPR 
screens which did not identify UGP2 as an essential gene 
in ESCs [66, 119]. We differentiated wild type, KI and KO 
ESCs into NSCs, using dual SMAD inhibition (Supple-
mentary Fig. 4a–c, online resource). Wild-type cells could 
readily differentiate into NSCs, having a normal morphology 
and marker expression, whereas differentiation of KI and KO 
cells was more variable and not all differentiations resulted 
in viable, proliferating NSCs. KO cells could not be propa-
gated for more than five passages under NSC culture condi-
tions (data not shown), which could indicate that the total 
absence of UGP2 protein is not tolerated in NSCs. When 
assessed by Western blotting, total UGP2 protein levels were 
reduced in KI cells and depleted in KO cells compared to 
wild type (Supplementary Fig. 4d, e, online resource).
Next, we performed RNA-seq of wild type, KI and KO 
ESCs and NSCs to assess how depletion of UGP2 upon 
NSC differentiation would impact the global transcriptome 
(Fig. 4, Supplementary Fig. 5, Supplementary Table 2, 
online resource). In agreement with normal proliferation and 
morphology of KI and KO ESCs, all ESCs shared a similar 
expression profile of pluripotency-associated genes and only 
few genes were differentially expressed between the three 
genotypes (Supplementary Fig. 5c, Supplementary Table 3, 
online resource). This indicates that the absence of UGP2 
in ESCs does not lead to major transcriptome alterations 
despite the central role of this enzyme in metabolism. Upon 
differentiation, cells from all genotypes expressed NSC 
markers (Supplementary Fig. 5f, online resource), but when 
comparing wild type and KO cells, we observed noticeable 
changes that were less pronounced in KI NSCs but still fol-
lowed a similar trend (Fig. 4a, b, Supplementary Fig. 5d, 
e, online resource). Gene enrichment analysis showed that 
genes downregulated in KO and KI cells were implicated 
in processes related to the extracellular matrix, cell–cell 
interactions and metabolism, while genes upregulated 
in KO and KI cells were enriched for synaptic processes 
and genes implicated in epilepsy (Fig. 4c, Supplementary 
Table 4, online resource). Both KO and KI cells showed 
an upregulation of neuronal expressed genes, indicating a 
tendency to differentiate prematurely. To validate RNA-seq 
findings, we tested several genes by qRT-PCR in wild type, 
KI and KO cells (Fig. 4d). We also included KO rescue 
cells, in which we had restored the expression of either the 
wild type or the mutant UGP2 long isoform, leading each 
to an approximately fourfold UGP2 overexpression at the 
NSC state compared to WT (Supplementary Fig. 4f, online 
resource). Amongst the tested genes was NNAT, which 
showed a significant upregulation in KI and KO cells, which 
was rescued by the restoration of UGP2 expression in KO 
NSCs. NNAT encodes neuronatin that stimulates glycogen 
synthesis by upregulating glycogen synthase and was previ-
ously found to be upregulated in Lafora disease. This lethal 
teenage-onset neurodegenerative disorder presenting with 
myoclonic epilepsy is caused by mutations in the ubiquitin 
ligase malin, leading to accumulation of altered polyglu-
cosans [107]. Malin can ubiquitinate neuronatin leading to 
its degradation. As reduced UGP2 expression might impact 
Fig. 4  RNA-seq of UGP2 mutant H9-derived neural stem cells. a 
Venn diagram showing the overlap between differentially expressed 
genes in UGP2 KO or KI NSCs that are upregulated (upper panel, 
genes with FDR < 0.05 and LogFC > 1) or downregulated (lower 
panel, genes with FDR < 0.05 and LogFC < -1) compared to wild-
type NSCs. b Box plot showing the distribution of gene expression 
levels [in Log2(RPKM + 1)] from RNA-seq for the groups of genes 
displayed in a, in wild type, UGP2 KI or KO NSCs. Boxes are IQR; 
line is median; and whiskers extend to 1.5 × the IQR (*p < 0.05; 
**p < 0.01, ***p < 0.001, unpaired t test, two tailed). c Enrich-
ment analysis using Enrichr [52] of up- or downregulated genes in 
NSCs from a for selected gene ontology sets, showing the five most 
enriched terms per set. Combined score and p value calculated by 
Enrichr are depicted (*p < 0.05; **p < 0.01; ***p < 0.001). d qRT-
PCR validation of differentially expressed genes from RNA-seq in 
wild type, UGP2 KI, UGP2 KO NSCs and KO NSCs rescued with 
either WT or MUT (Met12Val) transcript isoform 1, at p5 of NSC 
differentiation. Bar plot showing the mean fold change for the indi-
cated genes compared to wild type, normalized for the housekeeping 
gene TBP. Results of two biological and two independent techni-
cal replicates are plotted. Colors match the Venn diagram group to 
which the tested genes belong, from a. Error bars represent SEM; 
(*p < 0.05; **p < 0.01, ***p < 0.001, unpaired t test, one-tailed)
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glycogen production, it seems plausible that this results in 
compensatory NNAT upregulation and in downstream aber-
rations contributing to the patient phenotypes. Indeed, neu-
ronatin upregulation was shown to cause increased intracel-
lular  Ca2+ signaling, ER stress, proteasomal dysfunction and 
cell death in Lafora disease [92, 93], and was shown to be a 
stress-responsive protein in the outer segment of retina pho-
toreceptors [91, 95]. Another interesting gene upregulated in 
KI and KO NSCs and downregulated in rescue cell lines was 
the autism candidate gene FGFBP3 [87]. This secreted pro-
teoglycan that enhances FGF signaling is broadly expressed 
in brain [60], and functions as an extracellular chaperone for 
locally stored FGFs in the ECM, thereby influencing glucose 
metabolism by regulating rate-limiting enzymes in glucone-
ogenesis [102]. Other potentially relevant genes displaying 
the same expression trend were the heparan sulfate proteo-
glycan GPC2 (a marker of immature neurons [64, 72]), the 
helix–loop–helix transcription factor ID4 (a marker of post-
mitotic neurons [29]), and the signaling molecule FGFR3 
that has been implicated in epilepsy [73]. Genes downregu-
lated in KO cells and upregulated in rescue cells included 
urokinase-type plasminogen activator PLAU (deficiency in 
mouse models increases seizure susceptibility [53]), the gly-
coprotein GALNT7 (upregulation of which has been found to 
promote glioma cell invasion [45]) and the brain tumor gene 
MYBL1 (that has been shown to be regulated by O-linked 
N-acetylglucosamine [42]. Similar expression changes were 
observed in NSCs differentiated from induced pluripotent 
stem cells (iPSCs) that we had generated from family 1 
(Supplementary Fig. 6, online resource). Together, RNA-
seq showed that whereas the absence of UGP2 is tolerated in 
ESCs, its complete absence or reduced expression results in 
global transcriptome changes in NSCs, with many affected 
genes implicated in DEE-relevant pathways.
Absence of short UGP2 isoform leads to metabolic 
defects in neural stem cells
To investigate how reduced UGP2 expression levels in KO 
and KI cells would impact NSC metabolism, we investi-
gated the capacity to produce UDP-glucose in the pres-
ence of exogenously supplied glucose-1-phosphate and 
UTP. KO NSCs showed a severely reduced ability to pro-
duce UDP-glucose (Fig. 5a). This reduction was rescued 
by ectopic overexpression of both long wild type and long 
mutant UGP2. KI cells showed a slightly reduced activity 
in ESCs (Supplementary Fig. 7a, online resource), but a 
more strongly reduced activity in NSCs compared to wild 
type (Fig. 5a), correlating with total UGP2 expression levels 
(Supplementary Fig. 4d, e, online resource). Surprisingly, 
contrary to KO NSCs, KO ESC showed some residual 
capacity to produce UDP-glucose despite the complete 
absence of UGP2 (Supplementary Fig. 7a, online resource). 
This could indicate that a yet to be identified enzyme can 
partially take over the function of UGP2 in ESCs but not 
NSCs, which might explain the lack of expression changes 
in this cell type upon UGP2 loss. iPSCs showed similar 
results (Supplementary Fig. 7b, online resource). We next 
assessed the capacity to synthesize glycogen under low-oxy-
gen conditions by PAS staining, as it was previously shown 
that hypoxia triggers increased glycogen synthesis [78]. As 
expected, wild-type ESCs cultured for 48 h under hypoxia 
showed an intense cytoplasmic PAS staining in most cells 
(Supplementary Fig. 7c, d, online resource), while KO ESCs 
showed a severely reduced staining intensity. This indicates 
that under hypoxia conditions, the residual capacity of ESC 
to produce UDP-glucose in the absence of UGP2 is insuf-
ficient to produce glycogen. KI ESCs were indistinguishable 
from wild type (Supplementary Fig. 7d, online resource). At 
the NSC state, many KO cells kept at low-oxygen conditions 
for 48 h died (data not shown) and those KO cells that did 
survive were completely depleted from glycogen granules 
(Fig. 5b, c). This could be rescued by overexpression of both 
wild type and mutant long UGP2 isoform. KI NSCs showed 
a more severe reduction in PAS staining compared to the 
ESC state (Fig. 5b, c), and we observed similar findings in 
patient iPSC-derived NSCs (Supplementary Fig. 7e, online 
resource). Together, this further indicates that upon neural 
differentiation the isoform expression switch renders patient 
cells depleted of UGP2, leading to a reduced capacity to 
Fig. 5  Metabolic changes upon UGP2 loss. a UGP2 enzymatic activ-
ity in WT, UGP2 KI, KO and KO NSCs rescued with WT or MUT 
(Met12Val) isoform 1 of UGP2. Bar plot showing the mean of two 
replicate experiments, error bar is SEM. *p < 0.05; ***p < 0.001, 
unpaired t test, two tailed. b Representative pictures of PAS staining 
in WT, KI, KO and rescued NSCs. Nuclei are counterstained with 
hematoxylin (blue). Inserts show zoom-in of part of the cytoplasm. 
Note the presence of glycogen granules in WT NSCs, their dimin-
ished number in KI NSCs, their absence in KO NSCs and their reap-
pearance upon rescue with WT or MUT (Met12Val) isoform 1 of 
UGP2. c Quantification of the number of glycogen granules per cell 
in WT, UGP2 KI, KO and rescued NSCs, after 48  h culture under 
low-oxygen conditions. Shown is the average number of glycogen 
granules per cell, n = 80–100 cells per genotype. Error bars represent 
the SD. ***p < 0.001, unpaired t test, two tailed. d Western blotting 
detecting LAMP2 (upper panel) and the housekeeping control actin 
(lower panel) in cellular extracts from H9-derived NSCs that are WT, 
UGP2 KI, KO and KO cells rescued with WT or MUT (Met12Val) 
isoform 1 of UGP2. Glycosylated LAMP2 runs at ~ 110 kDa, whereas 
hypo-glycosylated LAMP2 is detected around 75  kDa. The absence 
of changes in LAMP2 glycosylation in KI cells is likely explained 
by a non-complete isoform switch upon in vitro NSC differentiation, 
resulting in residual UGP2 levels (see Supplementary Fig. 5d, online 
resource). e qRT-PCR expression analysis for UPR marker genes 
(spliced XBP1, HSPA5, ATF4 and EDEM) in WT, KI, KO and res-
cued NSCs. Shown is the mean fold change for the indicated genes 
compared to wild type, normalized for the housekeeping gene TBP. 
Results of two biological and two independent technical replicates are 
plotted, from two experiments. Error bars represent SEM; *p < 0.05; 
**p < 0.01, ***p < 0.001, unpaired t test, two tailed
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synthesize glycogen. This can directly be involved in the 
DEE phenotype, as, besides affecting energy metabolism, 
reduction of glycogen in brain has been shown to result 
in (1) impairment of synaptic plasticity [30]; (2) reduced 
clearance of extracellular potassium ions leading to neu-
ronal hypersynchronization and seizures [22, 63, 117]; (3) 
altered glutamate metabolism [88]. To investigate how 
reduced UDP-glucose levels would impact on glycosyla-
tion, we next investigated glycosylation levels by means 
of LAMP2, a lysosomal protein known to be extensively 
glycosylated both by N-linked and O-linked glycosylation 
[114]. We found that KO NSCs show hypoglycosylation of 
LAMP2 that is rescued by the overexpression of both WT 
and mutant long isoform (Fig. 5d). In contrast, in ESCs, 
no glycosylation defects were noticed (Supplementary 
Fig. 7f, online resource). Finally, we investigated whether 
the absence of UGP2, affecting protein glycosylation, could 
induce ER stress and thus unfolded protein response (UPR). 
Whereas in ESCs, the absence of UGP2 did not result in a 
detectable effect on UPR markers (Supplementary Fig. 7g, 
online resource), in NSCs we noticed an increased expres-
sion of these genes both in KO and in KI cells (Fig. 5e). 
This indicates that NSCs having UGP2 levels under a certain 
threshold are more prone to ER stress and UPR. In agree-
ment with this, we did not observe upregulation of UPR 
markers in patient-derived fibroblast, which have similar 
total UGP2 expression levels compared to controls (Sup-
plementary Fig. 7h, online resource). Together this indicates 
that upon differentiation to NSCs, KI cells become suffi-
ciently depleted of UGP2 to have reduced synthesis of UDP-
glucose, leading to defects in glycogen synthesis and protein 
glycosylation and to the activation of UPR response. Altera-
tions of these crucial processes are likely to be implicated in 
the pathogenesis leading to increased seizure susceptibility, 
altered brain microstructure and progressive microcephaly.
ugp2a and ugp2b double mutant zebrafish 
recapitulate metabolic changes during brain 
development, have an abnormal behavioral 
phenotype, visual disturbance, and increased 
seizure susceptibility
Finally, to model the consequences of the lack of UGP2 
in vivo, we generated zebrafish mutants for both ugp2a 
and ugp2b, the zebrafish homologs of UGP2, using 
CRISPR–Cas9 injections in fertilized oocytes in a back-
ground of a radial glia/neural stem cell reporter [51]. Double 
homozygous mutant lines having frameshift deletions for 
both genes confirmed by Sanger sequencing could be gener-
ated but the only viable combination, obtained with ugp2a 
loss, created a novel ATG in exon 2 of ugp2b, leading to a 
hypomorphic allele (Fig. 6a). Homozygous ugp2a/b mutant 
zebrafish had a normal gross morphology of brain and radial 
glial cells (Fig. 6b), showed a largely diminished activity to 
produce UDP-glucose in the presence of exogenously sup-
plied glucose-1-phosphate and UTP (Fig. 6c), and showed 
a reduction in c-fos expression levels, indicating reduced 
global neuronal activity (Fig. 6d). To monitor possible spon-
taneous seizures, we performed video tracking experiments 
of developing larvae under light–dark cycling conditions at 
5 days post-fertilization (dpf). Control larvae show increased 
locomotor activity under light conditions, and although ugp2 
double mutant larvae still responded to increasing light con-
ditions, they showed a strongly reduced activity (Fig. 6e, 
f). This could indicate that their capability to sense visual 
cues is diminished, or that their tectal processing of visual 
input is delayed, resulting in reduced movements. Strikingly, 
upon careful inspection, we noticed that ugp2 double mutant 
larvae did not show spontaneous eye movements, in contrast 
to age-matched control larvae (Fig. 6g, Supplemental Mov-
ies 2 and 3, online resource). Whereas we did not observe 
an obvious spontaneous epilepsy phenotype in these dou-
ble mutant larvae, upon stimulation with 4-aminopyridine 
(4-AP), a potent convulsant, double mutant larvae showed 
an increased frequency and duration of movements at high 
Fig. 6  Zebrafish disease modeling. a Schematic drawing of the ugp2a 
and ugp2b loci in zebrafish and the generated mutations. b Confo-
cal images (maximum projection of confocal Z-stacks) of the brain 
of wild type (left) and ugp2aΔ/Δ; ugp2bΔ/Δ mutant zebrafish larvae 
(right), both in an slc1a2b-citrine reporter background, at 4 days post-
fertilization (dpf). The lower panels are higher magnifications of the 
boxed regions indicated in the upper panels. Scale bar in upper panel 
is 100 µm, in lower panel 20 µm. In upper panel, Z = 45 with step size 
4 µm; in lower panel, Z = 30 with step size 2 µm. c Enzymatic activ-
ity in ugp2 double mutant zebrafish larvae at 4 and 5 dpf, compared 
to wild-type age-matched controls, showing reduced Ugp2 enzyme 
activity in double mutant zebrafish. d qRT-PCR for the neuronal 
activity marker c-fos in wild type and ugp2 double mutant larvae at 3 
dpf. For each group, 2 batches of 12 larvae were pooled. Shown is the 
mean fold change for the indicated genes compared to wild type, nor-
malized for the housekeeping gene gapdh. Error bars represent SEM; 
***p < 0.001, unpaired t test, two tailed. e Representative graph of 
a locomotion assay showing the total distance moved by larvae dur-
ing the dusk–dawn routine (total time: 3  h 12  min), n = 24 larvae 
per genotype. Gray shading shows the standard error of the mean. f 
Quantification of the total distance moved throughout the experiment 
from e excluding the dark period. g Quantification of the number of 
observed spontaneous eye movements during a 2-min observation 
in wild type and ugp2 double mutant larvae at 4 dpf. Each dot rep-
resents one larva; shown is the average and SD; ***p < 0.001, t test, 
two tailed. h Quantification of the frequency of movements at a speed 
of > 15 mm/s, for wild-type control and ugp2 double mutant zebrafish 
larvae at 4 dpf, treated with mock control or with 0.04 nM or 0.4 nM 
4-AP during a 35-min observation. Each dot represents a single 
larva; results of two experiments are shown, within total 24 larvae 
per condition. i Quantification of the movement duration at a speed 
of > 15 mm/s, for wild-type control and ugp2 double mutant zebrafish 
larvae at 4 dpf, treated with mock control or with 0.04 nM or 0.4 nM 
4-AP during a 35-min observation. Each dot represents a single larva; 
results of two experiments are shown, with in total 24 larvae per con-
dition. *p < 0.05, two-way ANOVA with Bonferoni post test
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velocity compared to controls, which might indicate an 
increased seizure susceptibility (Fig. 6h, i). Taken together, 
severely reduced Ugp2a/Ugp2b levels result in a behavior 
defect with reduced eye movements, indicating that also in 
zebrafish Ugp2 plays an important role in brain function.
UGP2 is an essential gene in humans and ATG 
mutations of tissue‑specific isoforms of essential 
genes potentially cause more rare genetic diseases
Several lines of evidence argue that UGP2 is essential in 
humans. First, no homozygous LoF variants or homozy-
gous exon-covering deletions for UGP2 are present in 
gnomAD or GeneDx controls, and homozygous variants in 
this gene are limited to non-coding changes, synonymous 
variants and five missense variants, together occurring only 
seven times homozygous (Supplementary Table 5, online 
resource). Also, no homozygous or compound heterozy-
gous UGP2 LoF variants were found in published studies 
on dispensable genes in human knockouts [70, 86, 99], or 
in the Centogene (CentoMD®) or GeneDx patient cohorts, 
encompassing together many thousands of individuals, fur-
ther indicating that this gene is intolerant to loss-of-function 
in a bi-allelic state. In addition, no homozygous deletions of 
the region encompassing UGP2 are present in DECIPHER 
[35] or ClinVar [54]. Second, UGP2 has been identified as 
an essential gene using gene-trap integrations [17] and in 
CRISPR–Cas9 LoF screens in several human cell types [5, 
15, 43, 113, 115]. Finally, studies in yeast [25, 26], fungus 
[58] and plants [21, 75, 116] consider the orthologs of UGP2 
as essential, and the absence of Ugp2 in mice is predicted 
to be lethal [104]. In flies, homozygous UGP knockouts are 
lethal while only hypomorphic compound heterozygous 
alleles are viable but have a severe movement defect with 
altered neuromuscular synaptogenesis due to glycosylation 
defects [48]. To further investigate the essentiality of UGP2, 
we performed differentiation experiments of our WT, KO 
and rescue ESCs. Differentiation of KO ESCs into hemat-
opoietic stem cells (HSCs) resulted in severe downregulation 
of GATA2 compared to wild-type cells, and this was restored 
in rescue cell lines (Fig. 7a). GATA2 is a key transcrip-
tion factor in the developing blood system, and knockout 
of Gata2 is embryonic lethal in mice due to defects in HSC 
generation and maintenance [28, 106]. Differentiation of 
ESCs into cardiomyocytes similarly affected key marker 
gene expression in KO cells, and these changes were restored 
upon UGP2 rescue (Fig. 7b, c). Whereas WT ESCs could 
generate beating cardiomyocytes after 10 days, these were 
not seen in KO ESCs. Taken together this argues that the 
complete absence of UGP2 in humans is probably incom-
patible with life, a hypothesis that cannot be tested directly. 
However, if true, this could well explain the occurrence of 
the unique recurrent mutation in all cases presented herein. 
Given the structure of the UGP2 locus (Fig. 2a), every LoF 
variant would affect either the long isoform, when located 
in the first 33 nucleotides of the cDNA sequence, or both the 
short and long isoforms when downstream to the ATG of 
the short isoform. Therefore, the short isoform start codon 
is the only mutational target that can disrupt specifically the 
short isoform. In this case, the Met12Val change introduced 
into the long isoform does not seem to disrupt UGP2 func-
tion to such an extent that this is intolerable and, therefore, 
allows development to proceed for most tissues. However, 
the lack of the short UGP2 isoform caused by the start codon 
mutation results in a depletion of functional UGP2 in tis-
sues where normally the short isoform is predominantly 
expressed. In brain, this reduction diminishes total UGP2 
levels below a threshold for normal development, causing 
a severe epileptic encephalopathy syndrome. Given the 
complexity of the human genome with 42,976 transcripts 
with RefSeq peptide IDs, perhaps also other genetic disor-
ders might be caused by such tissue-restricted depletion of 
essential proteins. Using a computational homology search 
of human proteins encoded by different isoforms, we have 
identified 1766 genes that share a similar structure to the 
UGP2 locus (e.g., a shorter protein isoform that is largely 
identical to the longer protein isoform, translated from an 
ATG that is contained within the coding sequence of the 
long isoform) (Fig. 7d). When filtering these genes for (1) 
those previously shown to be essential [10], (2) not associ-
ated with disease (e.g., no OMIM phenotype) and (3) those 
proteins where the shorter isoform is no more than 50 amino 
acids truncated at the N-terminal compared to the longer 
isoform, we identified 247 genes (Supplementary Table 6, 
online resource). When comparing the ratios of isoform-
specific reads obtained from different fetal RNA-seq data 
[46, 83, 94, 118], we noticed that many of these genes show 
Fig. 7  Essentiality of UGP2 and other disease candidate genes with a 
similar mutation mechanism. a qRT-PCR analysis of the hematopoi-
etic stem cell markers GATA2, LMO2 and RUNX1, after 12 days of 
differentiation of wild type, UGP2 KO and UGP2 KO rescue ESCs. 
Shown is the mean fold change for the indicated genes compared to 
wild type, normalized for the housekeeping gene TBP. Results of two 
biological and two technical replicates are plotted. Error bars repre-
sent SEM; *p < 0.05; **p < 0.01, ***p < 0.001, unpaired t test, two 
tailed. b As a, but now for cardiomyocyte differentiation at day 15, 
assessing expression of the cardiomyocyte markers TNNT2, MYL2 
and MYL7. c Bright-field image of cardiomyocyte cultures of wild 
type, UGP2 KO and rescue cells. Note the elongated organized mon-
olayer structure cardiomyocytes capable of beating in wild type and 
rescue cells that are absent in KO cultures. Scale bar is 400  µm. d 
Scheme showing the homology search to identify genes with a similar 
structure as UGP2, where ATG-altering mutations could affect a tis-
sue-specific isoform causing genetic disease. e Heat map showing the 
ratio of short isoform expression over total isoform expression from 
published RNA-seq data amongst 20 tissues for 83 out 247 essential 
genes that are not yet implicated in disease and in which the short 
and longer protein isoforms differ by less than 50 amino acids at the 
N-terminal
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differential isoform expression amongst multiple tissues, 
with many genes showing either expression of the long or 
the short isoform in a particular tissue (Fig. 7e). Homozy-
gous LoF variants or start codon altering mutations in these 
genes are rare in gnomAD (Supplementary Table 7, online 
resource), and it is tempting to speculate that mutations in 
start codons of these genes could be associated with human 
genetic diseases, as is the case for UGP2. Using mining of 
data from undiagnosed patients from our own exome data-
base, the Queen Square Genomic Center database and those 
from Centogene and GeneDx, we found evidence for several 
genes out of the 247 having rare, bi-allelic variants affecting 
the start codon of one of the isoforms that could be impli-
cated in novel disorders (unpublished observations) and 
give one such example in the Supplementary Note, online 
resource. Together, these findings highlight the relevance of 
mutations resulting in tissue-specific protein loss of essential 
genes for genetic disorders.
Discussion
Here we describe a recurrent variant in 22 individuals from 
15 families, affecting the start codon of the shorter isoform 
of the essential gene UGP2 as a novel cause of a severe 
DEE. Using in vitro and in vivo disease modeling, we pro-
vide evidence that the reduction of UGP2 expression in 
brain cells leads to global transcriptome changes, a reduced 
ability to produce glycogen, alterations in glycosylation 
and increased sensitivity to ER stress, which together can 
explain the phenotype observed in the patients. Most likely 
our findings in vitro underestimate the downstream effects in 
patient cells, as in fetal brain, the longer isoform expression 
is almost completely silenced and virtually all UGP2 come 
from the shorter isoform, which in patient cells cannot be 
translated. During our in vitro NSC differentiation, this iso-
form switch is less complete, leaving cells with the patient 
mutation with some residual UGP2. Strikingly, the clinical 
phenotype seems to be very similar in all cases, including 
intractable seizures, absence of developmental milestones, 
progressive microcephaly and a disturbance of vision, with 
retinal pigment changes observed in all patients who had 
undergone ophthalmological examination. Also, all patients 
seem to share similar, although mild, dysmorphisms, pos-
sibly making this condition a recognizable syndrome.
The involvement of UGP2 in genetic disease is surpris-
ing. Given its central role in nucleotide-sugar metabolism 
it is expected that loss of this essential protein would be 
incompatible with life and, therefore, loss-of-function should 
not be found in association with postnatal disease. Our data 
argue that indeed a total absence of UGP2 in all cells is 
lethal, but that tissue-specific loss, as caused here by the start 
codon alteration of an isoform important for brain, can be 
compatible with postnatal development but still results in a 
severe phenotype. Given that any other LoF variant across 
this gene would most likely affect both protein isoforms, this 
could also explain why only a single mutation is found in 
all individuals. The fact that the Met12Val long isoform was 
able to rescue the full KO phenotype indicates that the mis-
sense change introduced to the long protein isoform does not 
affect UGP2 function. As other variants at this start codon, 
even heterozygous, are not found, possibly missense variants 
encoding for leucine, lysine, threonine, arginine or isoleu-
cine (e.g., amino acids that would be encoded by alternative 
changes affecting the ATG codon) at this amino acid loca-
tion in the long isoform could not produce a functional pro-
tein and are, therefore, not tolerated. Although start codon 
mutations have previously been implicated in disease [16, 
19], there are no reports, to our knowledge, on disorders 
describing start codon alterations of other essential genes, 
leading to alterations of tissue-specific isoforms. Using a 
genome-wide homology search, we have identified a large 
list of other essential genes with a similar locus structure and 
variable isoform expression amongst tissues, where similar 
ATG-altering variants could affect tissue-relevant expres-
sion. An intriguing question is why evolution has resulted 
in a large number of genes encoding almost identical pro-
tein isoforms. It will be interesting to further explore the 
mutational landscape of these genes in cohorts of currently 
unexplained patients.
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7–10, JV, RM, HH analyzed WES; Family 9: JH phenotyped patient 11, 
KKK, ABA analyzed WES; Family 10: MA, MAA, MAS, MA, RA, 
LAQ, WQ, SC, KA, MHAH, SA, KA, AD, FA, DC and NK pheno-
typed patients 12 and 13, performed WES analysis and PGD; Family 
11: MDe, MYVM, MG, AGES and RM performed WES and pheno-
typed patients 14–17; Family 12: GRP phenotyped patient 19; Family 
13: HAC phenotyped patient 20, KKK, ABA analyzed WES; Family 
14, patient 21, and family 15, patient 22: KKK, ABA analyzed WES. 
RT, KR, KKK, PB, ABA, RM, HH provided genetic data for popula-
tion analysis. TSB identified patient 1, conceived the study, obtained 
funding, supervised the lab work and wrote the manuscript, with input 
from all main authors. All authors approved the final version of the 
manuscript.
Compliance with ethical standards 
Conflict of interest KGM, AB, RT and KR are employees of GeneDx, 
Inc. KR holds stock in OPKO Health, Inc. KKK, PB and ABA are 
employees of CENTOGENE AG.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. (2010) Baluchistan i. Geography, history and ethnography. Ency-
clopædia Iranica City, pp fasc. 6, pp 598–632
 2. Adeva-Andany MM, Gonzalez-Lucan M, Donapetry-Garcia C, 
Fernandez-Fernandez C, Ameneiros-Rodriguez E (2016) Glyco-
gen metabolism in humans. BBA Clin 5:85–100
 3. Anders S, Pyl PT, Huber W (2015) HTSeq–a Python framework 
to work with high-throughput sequencing data. Bioinformatics 
31:166–169
 4. Arranz AM, Perkins KL, Irie F, Lewis DP, Hrabe J, Xiao F et al 
(2014) Hyaluronan deficiency due to Has3 knock-out causes 
altered neuronal activity and seizures via reduction in brain 
extracellular space. J Neurosci 34:6164–6176
 5. Bakke J, Wright WC, Zamora AE, Oladimeji P, Crawford JC, 
Brewer CT et al (2019) Genome-wide CRISPR screen reveals 
PSMA6 to be an essential gene in pancreatic cancer cells. BMC 
Cancer 19:253
 6. Barakat TS, Ghazvini M, de Hoon B, Li T, Eussen B, Douben H 
et al (2015) Stable X chromosome reactivation in female human 
induced pluripotent stem cells. Stem Cell Rep 4:199–208
 7. Barakat TS, Gribnau J (2015) Generation of knockout alleles 
by RFLP based BAC targeting of polymorphic embryonic stem 
cells. Methods Mol Biol 1227:143–180
 8. Barakat TS, Gribnau J (2010) X chromosome inactivation and 
embryonic stem cells. Adv Exp Med Biol 695:132–154
 9. Barakat TS, Halbritter F, Zhang M, Rendeiro AF, Perenthaler 
E, Bock C et al (2018) Functional dissection of the enhancer 
repertoire in human embryonic stem cells. Cell Stem Cell 
23(276–288):e278
 10. Bartha I, di Iulio J, Venter JC, Telenti A (2018) Human gene 
essentiality. Nat Rev Genet 19:51–62
 11. Bayer SA, Altman J (2004) Atlas of human central nervous sys-
tem development: the human brain during the third trimester, vol 
2. CRC Press, New York
 12. Bayer SA, Altman J (2005) Atlas of human central nervous sys-
tem development: the human brain during the second trimester, 
vol 3. CRC Press, New York
 13. Bayer SA, Altman J (2006) Atlas of human central nervous sys-
tem development: the human brain during the late first trimester, 
vol 4. CRC Press, New York
 14. Bayer SA, Altman J (2008) Atlas of human central nervous sys-
tem development: the human brain during the early first trimes-
ter, vol 5. CRC Press, New York
 15. Bertomeu T, Coulombe-Huntington J, Chatr-Aryamontri A, 
Bourdages KG, Coyaud E, Raught B et al (2018) A high-resolu-
tion genome-wide CRISPR/Cas9 viability screen reveals struc-
tural features and contextual diversity of the human cell-essential 
proteome. Mol Cell Biol 38:10
 16. Binder J, Hofmann S, Kreisel S, Wohrle JC, Bazner H, Krauss 
JK et al (2003) Clinical and molecular findings in a patient with 
a novel mutation in the deafness-dystonia peptide (DDP1) gene. 
Brain 126:1814–1820
 17. Blomen VA, Majek P, Jae LT, Bigenzahn JW, Nieuwenhuis J, 
Staring J et al (2015) Gene essentiality and synthetic lethality in 
haploid human cells. Science 350:1092–1096
 18. Brinkman EK, Chen T, Amendola M, van Steensel B (2014) 
Easy quantitative assessment of genome editing by sequence 
trace decomposition. Nucleic Acids Res 42:e168
 19. Caridi G, Dagnino M, Lugani F, Shalev SA, Campagnoli M, Gal-
liano M et al (2013) A novel mutation in the albumin gene (c.1A 
%3e C) resulting in analbuminemia. Eur J Clin Invest 43:72–78
 20. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sad-
elain M, Studer L (2009) Highly efficient neural conversion of 
human ES and iPS cells by dual inhibition of SMAD signaling. 
Nat Biotechnol 27:275–280
 21. Chen R, Zhao X, Shao Z, Wei Z, Wang Y, Zhu L et al (2007) 
Rice UDP-glucose pyrophosphorylase1 is essential for pollen 
callose deposition and its cosuppression results in a new type of 
thermosensitive genic male sterility. Plant Cell 19:847–861
 22. Choi HB, Gordon GR, Zhou N, Tai C, Rungta RL, Martinez J 
et al (2012) Metabolic communication between astrocytes and 
neurons via bicarbonate-responsive soluble adenylyl cyclase. 
Neuron 75:1094–1104
 Acta Neuropathologica
1 3
 23. Consortium GT (2013) The genotype-tissue expression (GTEx) 
project. Nat Genet 45:580–585
 24. Cope EC, Gould E (2019) Adult Neurogenesis, glia, and the 
extracellular matrix. Cell Stem Cell 24(5):690–705
 25. Daran JM, Bell W, Francois J (1997) Physiological and mor-
phological effects of genetic alterations leading to a reduced 
synthesis of UDP-glucose in Saccharomyces cerevisiae. FEMS 
Microbiol Lett 153:89–96
 26. Daran JM, Dallies N, Thines-Sempoux D, Paquet V, Francois J 
(1995) Genetic and biochemical characterization of the UGP1 
gene encoding the UDP-glucose pyrophosphorylase from Sac-
charomyces cerevisiae. Eur J Biochem 233:520–530
 27. de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg 
E, Kluin PM et al (2011) Gene expression profiling in the leuke-
mic stem cell-enriched CD34 + fraction identifies target genes 
that predict prognosis in normal karyotype AML. Leukemia 
25:1825–1833
 28. de Pater E, Kaimakis P, Vink CS, Yokomizo T, Yamada-Inagawa 
T, van der Linden R et al (2013) Gata2 is required for HSC gen-
eration and survival. J Exp Med 210:2843–2850
 29. Diotel N, Beil T, Strahle U, Rastegar S (2015) Differential 
expression of id genes and their potential regulator znf238 in 
zebrafish adult neural progenitor cells and neurons suggests 
distinct functions in adult neurogenesis. Gene Expr Patterns 
19:1–13
 30. Duran J, Saez I, Gruart A, Guinovart JJ, Delgado-Garcia JM 
(2013) Impairment in long-term memory formation and learning-
dependent synaptic plasticity in mice lacking glycogen synthase 
in the brain. J Cereb Blood Flow Metab 33:550–556
 31. Epi25 Collaborative, Electronic address sbuea, Epi C (2019) 
Ultra-rare genetic variation in the epilepsies: a whole-exome 
sequencing study of 17,606 individuals. Am J Hum Genet 1:4
 32. Epi KC, Phenome E, Genome P, Allen AS, Berkovic SF, Cos-
sette P, Delanty N et al (2013) De novo mutations in epileptic 
encephalopathies. Nature 501:217–221
 33. Exome Variant Server NHLBI GO Exome Sequencing Project 
(ESP) Seattle WA (accessed Juli 2019).
 34. Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Sellars E, 
Nezhadi SH et al (2019) Iranome: a catalog of genomic varia-
tions in the Iranian population. Hum Mutat 1:4
 35. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan 
D et al (2009) DECIPHER: database of chromosomal imbalance 
and phenotype in humans using Ensembl resources. Am J Hum 
Genet 84:524–533
 36. Flores-Diaz M, Alape-Giron A, Persson B, Pollesello P, Moos 
M, von Eichel-Streiber C et al (1997) Cellular UDP-glucose defi-
ciency caused by a single point mutation in the UDP-glucose 
pyrophosphorylase gene. J Biol Chem 272:23784–23791
 37. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den 
Dunnen JT (2011) LOVD vol 2.0: the next generation in gene 
variant databases. Hum Mutat 32:557–563
 38. Fuhring J, Damerow S, Fedorov R, Schneider J, Munster-Kuhnel 
AK, Gerardy-Schahn R (2013) Octamerization is essential for 
enzymatic function of human UDP-glucose pyrophosphorylase. 
Glycobiology 23:426–437
 39. Fuhring JI, Cramer JT, Schneider J, Baruch P, Gerardy-Schahn R, 
Fedorov R (2015) A quaternary mechanism enables the complex 
biological functions of octameric human UDP-glucose pyroph-
osphorylase, a key enzyme in cell metabolism. Sci Rep 5:9618
 40. Gonzalez M, Falk MJ, Gai X, Postrel R, Schule R, Zuchner S 
(2015) Innovative genomic collaboration using the GENESIS 
(GEM.app) platform. Hum Mutat 36:950–956
 41. Gostynska KB, Nijenhuis M, Lemmink H, Pas HH, Pasmooij 
AM, Lang KK et al (2015) Mutation in exon 1a of PLEC, leading 
to disruption of plectin isoform 1a, causes autosomal-recessive 
skin-only epidermolysis bullosa simplex. Hum Mol Genet 
24:3155–3162
 42. Guo H, Zhang B, Nairn AV, Nagy T, Moremen KW, Buckhaults P 
et al (2017) O-Linked N-acetylglucosamine (O-GlcNAc) expres-
sion levels epigenetically regulate colon cancer tumorigenesis 
by affecting the cancer stem cell compartment via modulat-
ing expression of transcriptional factor MYBL1. J Biol Chem 
292:4123–4137
 43. Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown 
KR, MacLeod G et al (2015) High-resolution CRISPR screens 
reveal fitness genes and genotype-specific cancer liabilities. Cell 
163:1515–1526
 44. Higuita JC, Alape-Giron A, Thelestam M, Katz A (2003) A point 
mutation in the UDP-glucose pyrophosphorylase gene results in 
decreases of UDP-glucose and inactivation of glycogen synthase. 
Biochem J 370:995–1001
 45. Hua S, Li H, Liu Y, Zhang J, Cheng Y, Dai C (2018) High 
expression of GALNT7 promotes invasion and proliferation of 
glioma cells. Oncol Lett 16:6307–6314
 46. Hwang T, Park CK, Leung AK, Gao Y, Hyde TM, Kleinman JE 
et al (2016) Dynamic regulation of RNA editing in human brain 
development and disease. Nat Neurosci 19:1093–1099
 47. Jenkins ZA, Macharg A, Chang CY, van Kogelenberg M, Morgan 
T, Frentz S et al (2018) Differential regulation of two FLNA 
transcripts explains some of the phenotypic heterogeneity in the 
loss-of-function filaminopathies. Hum Mutat 39:103–113
 48. Jumbo-Lucioni PP, Parkinson WM, Kopke DL, Broadie K 
(2016) Coordinated movement, neuromuscular synaptogenesis 
and trans-synaptic signaling defects in Drosophila galactosemia 
models. Hum Mol Genet 25:3699–3714
 49. Kalser J, Cross JH (2018) The epileptic encephalopathy jungle—
from Dr West to the concepts of aetiology-related and develop-
mental encephalopathies. Curr Opin Neurol 31:216–222
 50. Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced 
aligner with low memory requirements. Nat Methods 12:357–360
 51. Kuil LE, Lopez Marti A, Carreras Mascaro A, van den Bosch 
JC, van den Berg P, van der Linde HC et al (2019) Hexb enzyme 
deficiency leads to lysosomal abnormalities in radial glia and 
microglia in zebrafish brain development. Glia 67:1705–1718
 52. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan 
Q, Wang Z et  al (2016) Enrichr: a comprehensive gene set 
enrichment analysis web server 2016 update. Nucleic Acids Res 
44:W90–97
 53. Kyyriainen J, Bolkvadze T, Koivisto H, Lipponen A, Perez LO, 
Ekolle Ndode-Ekane X et al (2019) Deficiency of urokinase-type 
plasminogen activator and its receptor affects social behavior and 
increases seizure susceptibility. Epilepsy Res 151:67–74
 54. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church 
DM et al (2014) ClinVar: public archive of relationships among 
sequence variation and human phenotype. Nucleic Acids Res 
42:D980–985
 55. Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gen-
tleman R et al (2013) Software for computing and annotating 
genomic ranges. PLoS Comput Biol 9:e1003118
 56. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fen-
nell T et al (2016) Analysis of protein-coding genetic variation 
in 60,706 humans. Nature 536:285–291
 57. Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS et al (2016) 
Point mutations in exon 1B of APC reveal gastric adenocarci-
noma and proximal polyposis of the stomach as a familial adeno-
matous polyposis variant. Am J Hum Genet 98:830–842
 58. Li M, Chen T, Gao T, Miao Z, Jiang A, Shi L et al (2015) UDP-
glucose pyrophosphorylase influences polysaccharide synthesis, 
cell wall components, and hyphal branching in Ganoderma luci-
dum via regulation of the balance between glucose-1-phosphate 
and UDP-glucose. Fungal Genet Biol 82:251–263
Acta Neuropathologica 
1 3
 59. Li S, Hu Z, Zhao Y, Huang S, He X (2019) Transcriptome-wide 
analysis reveals the landscape of aberrant alternative splicing 
events in liver cancer. Hepatology 69:359–375
 60. Li Y, Sun S, Ding Z, Yang C, Zhang G, Jiang Q et al (2018) Tem-
poral and spatial expression of fgfbp genes in zebrafish. Gene 
659:128–136
 61. Li Y, Zhuang H, Zhang X, Li Y, Liu Y, Yi X et al (2018) Multi-
omics integration reveals the landscape of prometastasis metabo-
lism in hepatocellular carcinoma. Mol Cell Proteom 17:607–618
 62. Lindhout M, Rubio-Gozalbo ME, Bakker JA, Bierau 
J (2010) Direct non-radioactive assay of galactose-
1-phosphate:uridyltransferase activity using high performance 
liquid chromatography. Clin Chim Acta 411:980–983
 63. Lopez-Ramos JC, Duran J, Gruart A, Guinovart JJ, Delgado-Gar-
cia JM (2015) Role of brain glycogen in the response to hypoxia 
and in susceptibility to epilepsy. Front Cell Neurosci 9:431
 64. Lugert S, Kremer T, Jagasia R, Herrmann A, Aigner S, Giach-
ino C et al (2017) Glypican-2 levels in cerebrospinal fluid pre-
dict the status of adult hippocampal neurogenesis. Sci Rep 
7:46543
 65. Magee C, Nurminskaya M, Linsenmayer TF (2001) UDP-glu-
cose pyrophosphorylase: up-regulation in hypertrophic carti-
lage and role in hyaluronan synthesis. Biochem J 360:667–674
 66. Mair B, Tomic J, Masud SN, Tonge P, Weiss A, Usaj M et al 
(2019) Essential gene profiles for human pluripotent stem cells 
identify uncharacterized genes and substrate dependencies. 
Cell Rep 27(2):599–615.e12
 67. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis 
K, Kernytsky A et al (2010) The genome analysis toolkit: a 
MapReduce framework for analyzing next-generation DNA 
sequencing data. Genome Res 20:1297–1303
 68. McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE 
(2016) The genetic landscape of the epileptic encephalopathies 
of infancy and childhood. Lancet Neurol 15:304–316
 69. Mencacci NE, Kamsteeg EJ, Nakashima K, R’Bibo L, Lynch 
DS, Balint B et al (2016) De novo mutations in PDE10A cause 
childhood-onset chorea with bilateral striatal lesions. Am J 
Hum Genet 98:763–771
 70. Narasimhan VM, Hunt KA, Mason D, Baker CL, Karczewski 
KJ, Barnes MR et al (2016) Health and population effects of 
rare gene knockouts in adult humans with related parents. Sci-
ence 352:474–477
 71. Nashabat M, Al Qahtani XS, Almakdob S, Altwaijri W, Ba-
Armah DM, Hundallah K et al (2019) The landscape of early 
infantile epileptic encephalopathy in a consanguineous popula-
tion. Seizure 69:154–172
 72. Oikari LE, Okolicsanyi RK, Qin A, Yu C, Griffiths LR, Haupt 
LM (2016) Cell surface heparan sulfate proteoglycans as novel 
markers of human neural stem cell fate determination. Stem 
Cell Res 16:92–104
 73. Okazaki T, Saito Y, Ueda R, Awashima T, Nishimura Y, Yuasa 
I et al (2017) Epileptic phenotype of FGFR3-related bilateral 
medial temporal lobe dysgenesis. Brain Dev 39:67–71
 74. Papuc SM, Abela L, Steindl K, Begemann A, Simmons TL, 
Schmitt B et al (2019) The role of recessive inheritance in 
early-onset epileptic encephalopathies: a combined whole-
exome sequencing and copy number study. Eur J Hum Genet 
27:408–421
 75. Park JI, Ishimizu T, Suwabe K, Sudo K, Masuko H, Hakozaki 
H et al (2010) UDP-glucose pyrophosphorylase is rate limiting 
in vegetative and reproductive phases in Arabidopsis thaliana. 
Plant Cell Physiol 51:981–996
 76. Perenthaler E, Yousefi S, Niggl E, Barakat TS (2019) Beyond 
the exome: the non-coding genome and enhancers in neurode-
velopmental disorders and malformations of cortical develop-
ment. Front Cell Neurosci 13:352
 77. Perkins KL, Arranz AM, Yamaguchi Y, Hrabetova S (2017) 
Brain extracellular space, hyaluronan, and the prevention of 
epileptic seizures. Rev Neurosci 28:869–892
 78. Pescador N, Villar D, Cifuentes D, Garcia-Rocha M, Ortiz-
Barahona A, Vazquez S et al (2010) Hypoxia promotes gly-
cogen accumulation through hypoxia inducible factor (HIF)-
mediated induction of glycogen synthase 1. PLoS ONE 
5:e9644
 79. Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H 
et al (2019) g:Profiler: a web server for functional enrichment 
analysis and conversions of gene lists (2019 update). Nucleic 
Acids Res 47:W191–W198
 80. Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec 
J, Duvernois-Berthet E et al (2016) Improved genome editing 
efficiency and flexibility using modified oligonucleotides with 
TALEN and CRISPR-Cas9 nucleases. Cell Rep 14:2263–2272
 81. Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M (2019) 
CADD: predicting the deleteriousness of variants throughout the 
human genome. Nucleic Acids Res 47:D886–D894
 82. Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini 
F et al (2016) Clinical application of whole-exome sequencing 
across clinical indications. Genet Med 18:696–704
 83. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, 
Bilenky M, Yen A et al (2015) Integrative analysis of 111 refer-
ence human epigenomes. Nature 518:317–330
 84. Robbins SM, Thimm MA, Valle D, Jelin AC (2019) Genetic 
diagnosis in first or second trimester pregnancy loss using exome 
sequencing: a systematic review of human essential genes. J 
Assist Reprod Genet 36:1539–1548
 85. Robinson MD, McCarthy DJ, Smyth GK (2010) edgeR: a bio-
conductor package for differential expression analysis of digital 
gene expression data. Bioinformatics 26:139–140
 86. Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, 
Khetarpal SA et al (2017) Human knockouts and phenotypic 
analysis in a cohort with a high rate of consanguinity. Nature 
544:235–239
 87. Salyakina D, Cukier HN, Lee JM, Sacharow S, Nations LD, Ma 
D et al (2011) Copy number variants in extended autism spec-
trum disorder families reveal candidates potentially involved in 
autism risk. PLoS ONE 6:e26049
 88. Schousboe A, Sickmann HM, Walls AB, Bak LK, Waagepetersen 
HS (2010) Functional importance of the astrocytic glycogen-
shunt and glycolysis for maintenance of an intact intra/extracel-
lular glutamate gradient. Neurotox Res 18:94–99
 89. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) Muta-
tionTaster2: mutation prediction for the deep-sequencing age. 
Nat Methods 11:361–362
 90. Scott EM, Halees A, Itan Y, Spencer EG, He Y, Azab MA et al 
(2016) Characterization of Greater Middle Eastern genetic 
variation for enhanced disease gene discovery. Nat Genet 
48:1071–1076
 91. Sel S, Patzel E, Poggi L, Kaiser D, Kalinski T, Schicht M et al 
(2017) Temporal and spatial expression pattern of Nnat during 
mouse eye development. Gene Express Patterns 23–24:7–12
 92. Sharma J, Mukherjee D, Rao SN, Iyengar S, Shankar SK, Sat-
ishchandra P et al (2013) Neuronatin-mediated aberrant calcium 
signaling and endoplasmic reticulum stress underlie neuropathol-
ogy in Lafora disease. J Biol Chem 288:9482–9490
 93. Sharma J, Rao SN, Shankar SK, Satishchandra P, Jana NR (2011) 
Lafora disease ubiquitin ligase malin promotes proteasomal deg-
radation of neuronatin and regulates glycogen synthesis. Neuro-
biol Dis 44:133–141
 94. Shih HP, Seymour PA, Patel NA, Xie R, Wang A, Liu PP et al 
(2015) A gene regulatory network cooperatively controlled by 
Pdx1 and Sox9 governs lineage allocation of foregut progenitor 
cells. Cell Rep 13:326–336
 Acta Neuropathologica
1 3
 95. Shinde V, Pitale PM, Howse W, Gorbatyuk O, Gorbatyuk M 
(2016) Neuronatin is a stress-responsive protein of rod photore-
ceptors. Neuroscience 328:1–8
 96. Snoeijen-Schouwenaars FM, van Ool JS, Verhoeven JS, van 
Mierlo P, Braakman HMH, Smeets EE et al (2019) Diagnostic 
exome sequencing in 100 consecutive patients with both epilepsy 
and intellectual disability. Epilepsia 60:155–164
 97. Sobreira N, Schiettecatte F, Valle D, Hamosh A (2015) Gen-
eMatcher: a matching tool for connecting investigators with an 
interest in the same gene. Hum Mutat 36:928–930
 98. Soleman S, Filippov MA, Dityatev A, Fawcett JW (2013) Tar-
geting the neural extracellular matrix in neurological disorders. 
Neuroscience 253:194–213
 99. Sulem P, Helgason H, Oddson A, Stefansson H, Gudjonsson SA, 
Zink F et al (2015) Identification of a large set of rare complete 
human knockouts. Nat Genet 47:448–452
 100. Ta-Shma A, Khan TN, Vivante A, Willer JR, Matak P, Jalas 
C et al (2017) Mutations in TMEM260 cause a pediatric neu-
rodevelopmental, cardiac, and renal syndrome. Am J Hum Genet 
100:666–675
 101. Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH, Toh HC et al 
(2014) Novel proteomic biomarker panel for prediction of 
aggressive metastatic hepatocellular carcinoma relapse in surgi-
cally resectable patients. J Proteome Res 13:4833–4846
 102. Tassi E, Garman KA, Schmidt MO, Ma X, Kabbara KW, Uren A 
et al (2018) Fibroblast growth factor binding protein 3 (FGFBP3) 
impacts carbohydrate and lipid metabolism. Sci Rep 8:15973
 103. Thorsen K, Schepeler T, Oster B, Rasmussen MH, Vang S, Wang 
K et al (2011) Tumor-specific usage of alternative transcription 
start sites in colorectal cancer identified by genome-wide exon 
array analysis. BMC Genom 12:505
 104. Tian D, Wenlock S, Kabir M, Tzotzos G, Doig AJ, Hentges KE 
(2018) Identifying mouse developmental essential genes using 
machine learning. Dis Model Mech 11:4
 105. Trujillano D, Bertoli-Avella AM, Kumar Kandaswamy K, Weiss 
ME, Koster J, Marais A et al (2017) Clinical exome sequencing: 
results from 2819 samples reflecting 1000 families. Eur J Hum 
Genet 25:176–182
 106. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M 
et al (1994) An early haematopoietic defect in mice lacking the 
transcription factor GATA-2. Nature 371:221–226
 107. Turnbull J, Tiberia E, Striano P, Genton P, Carpenter S, Ackerley 
CA et al (2016) Lafora disease. Epilept Disord 18:38–62
 108. Turnquist RL, Gillett TA, Hansen RG (1974) Uridine diphos-
phate glucose pyrophosphorylase. Crystallization and properties 
of the enzyme from rabbit liver and species comparisons. J Biol 
Chem 249:7695–7700
 109. Turton KB, Esnault S, Delain LP, Mosher DF (2016) Merging 
absolute and relative quantitative PCR data to quantify STAT3 
splice variant transcripts. J Vis Exp 1:4
 110. Vigetti D, Viola M, Karousou E, De Luca G, Passi A (2014) 
Metabolic control of hyaluronan synthases. Matrix Biol 35:8–13
 111. Wang L, Xiong L, Wu Z, Miao X, Liu Z, Li D et al (2018) 
Expression of UGP2 and CFL1 expression levels in benign and 
malignant pancreatic lesions and their clinicopathological sig-
nificance. World J Surg Oncol 16:11
 112. Wang Q, Yang ZL, Zou Q, Yuan Y, Li J, Liang L et al (2016) 
SHP2 and UGP2 are biomarkers for progression and poor prog-
nosis of gallbladder cancer. Cancer Invest 34:255–264
 113. Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ 
et al (2015) Identification and characterization of essential genes 
in the human genome. Science 350:1096–1101
 114. Wang X, Ju L, Fan J, Zhu Y, Liu X, Zhu K et al (2014) Histone 
H3K4 methyltransferase Mll1 regulates protein glycosylation and 
tunicamycin-induced apoptosis through transcriptional regula-
tion. Biochim Biophys Acta 1843:2592–2602
 115. Wang X, Wang S, Troisi EC, Howard TP, Haswell JR, Wolf BK 
et al (2019) BRD9 defines a SWI/SNF sub-complex and consti-
tutes a specific vulnerability in malignant rhabdoid tumors. Nat 
Commun 10:1881
 116. Woo MO, Ham TH, Ji HS, Choi MS, Jiang W, Chu SH et al 
(2008) Inactivation of the UGPase1 gene causes genic male ste-
rility and endosperm chalkiness in rice (Oryza sativa L.). Plant 
J 54:190–204
 117. Xu J, Song D, Xue Z, Gu L, Hertz L, Peng L (2013) Require-
ment of glycogenolysis for uptake of increased extracellular K 
+ in astrocytes: potential implications for K + homeostasis and 
glycogen usage in brain. Neurochem Res 38:472–485
 118. Yan L, Guo H, Hu B, Li R, Yong J, Zhao Y et al (2016) Epig-
enomic landscape of human fetal brain, heart, and liver. J Biol 
Chem 291:4386–4398
 119. Yilmaz A, Peretz M, Aharony A, Sagi I, Benvenisty N (2018) 
Defining essential genes for human pluripotent stem cells 
by CRISPR-Cas9 screening in haploid cells. Nat Cell Biol 
20:610–619
 120. Ying D, Sham PC, Smith DK, Zhang L, Lau YL, Yang W (2015) 
HaploShare: identification of extended haplotypes shared by 
cases and evaluation against controls. Genome Biol 16:92
 121. Yu Q, Zheng X (2012) The crystal structure of human UDP-
glucose pyrophosphorylase reveals a latch effect that influences 
enzymatic activity. Biochem J 442:283–291
 122. Zeng C, Xing W, Liu Y (2019) Identification of UGP2 as a pro-
gression marker that promotes cell growth and motility in human 
glioma. J Cell Biochem 120:12489–12499
 123. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tana-
seichuk O et al (2019) Metascape provides a biologist-oriented 
resource for the analysis of systems-level datasets. Nat Commun 
10:1523
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Acta Neuropathologica 
1 3
Affiliations
Elena Perenthaler1 · Anita Nikoncuk1 · Soheil Yousefi1 · Woutje M. Berdowski1 · Maysoon Alsagob2 · Ivan Capo3 · 
Herma C. van der Linde1 · Paul van den Berg1 · Edwin H. Jacobs1 · Darija Putar1 · Mehrnaz Ghazvini4 · 
Eleonora Aronica5,6 · Wilfred F. J. van IJcken7 · Walter G. de Valk1 · Evita Medici‑van den Herik8 · 
Marjon van Slegtenhorst1 · Lauren Brick9 · Mariya Kozenko9 · Jennefer N. Kohler10 · Jonathan A. Bernstein11 · 
Kristin G. Monaghan12 · Amber Begtrup12 · Rebecca Torene12 · Amna Al Futaisi13 · Fathiya Al Murshedi14 · 
Renjith Mani13 · Faisal Al Azri15 · Erik‑Jan Kamsteeg16 · Majid Mojarrad17,18,19 · Atieh Eslahi17,20 · 
Zaynab Khazaei19 · Fateme Massinaei Darmiyan21 · Mohammad Doosti22 · Ehsan Ghayoor Karimiani23,24 · 
Jana Vandrovcova25 · Faisal Zafar26 · Nuzhat Rana26 · Krishna K. Kandaswamy27 · Jozef Hertecant28 · Peter Bauer27 · 
Mohammed A. AlMuhaizea29 · Mustafa A. Salih30 · Mazhor Aldosary2 · Rawan Almass2 · Laila Al‑Quait2 · 
Wafa Qubbaj31 · Serdar Coskun31 · Khaled O. Alahmadi32 · Muddathir H. A. Hamad30 · Salem Alwadaee31 · 
Khalid Awartani33 · Anas M. Dababo31 · Futwan Almohanna34 · Dilek Colak35 · Mohammadreza Dehghani36,37 · 
Mohammad Yahya Vahidi Mehrjardi38 · Murat Gunel39 · A. Gulhan Ercan‑Sencicek39,40 · Gouri Rao Passi41 · 
Huma Arshad Cheema42 · Stephanie Efthymiou25 · Henry Houlden25 · Aida M. Bertoli‑Avella27 · Alice S. Brooks1 · 
Kyle Retterer12 · Reza Maroofian25 · Namik Kaya2 · Tjakko J. van Ham1 · Tahsin Stefan Barakat1 
 * Tahsin Stefan Barakat 
 t.barakat@erasmusmc.nl
1 Department of Clinical Genetics, Erasmus MC University 
Medical Center, Rotterdam, The Netherlands
2 Department of Genetics, King Faisal Specialist 
Hospital and Research Centre, Riyadh 11211, 
Kingdom of Saudi Arabia
3 Department for Histology and Embryology, Faculty 
of Medicine Novi Sad, University of Novi Sad, Novi Sad, 
Serbia
4 iPS Cell Core Facility, Erasmus MC University Medical 
Center, Rotterdam, The Netherlands
5 Department of (Neuro)Pathology, Amsterdam Neuroscience, 
Amsterdam UMC, University of Amsterdam, Amsterdam, 
The Netherlands
6 Stichting Epilepsie Instellingen Nederland (SEIN), Zwolle, 
The Netherlands
7 Center for Biomics, Department of Cell Biology, Erasmus 
MC University Medical Center, Rotterdam, The Netherlands
8 Department of Neurology, Erasmus MC University Medical 
Center, Rotterdam, The Netherlands
9 Division of Genetics, McMaster Children’s Hospital, 
Hamilton, ON L8S 4J9, Canada
10 Division of Cardiovascular Medicine, Stanford University 
School of Medicine, Stanford, CA 94035, USA
11 Division of Medical Genetics, Department of Pediatrics, 
Stanford University School of Medicine, Stanford, 
CA 94035, USA
12 GeneDx, Gaithersburg, MD 20877, USA
13 Department of Child Health, College of Medicine and Health 
Sciences, Sultan Qaboos University, Muscat, Oman
14 Genetic and Developmental Medicine Clinic, Sultan Qaboos 
University Hospital, Muscat, Oman
15 Department of Radiology and Molecular Imaging, Sultan 
Qaboos University Hospital, Muscat, Oman
16 Department of Human Genetics, Radboud University 
Medical Centre, Nijmegen, The Netherlands
17 Department of Medical Genetics, Faculty of Medicine, 
Mashhad University of Medical Sciences, Mashhad, Iran
18 Medical Genetics Research Center, Mashhad University 
of Medical Sciences, Mashhad, Iran
19 Genetic Center of Khorasan Razavi, Mashhad, Iran
20 Student Research Committee, Faculty of Medicine, Mashhad 
University of Medical Sciences, Mashhad, Iran
21 Genetic Counseling Center, Welfare Organization of Sistan 
and Baluchestan, Zahedan, Iran
22 Department Medical Genetics, Next Generation Genetic 
Polyclinic, Mashhad, Iran
23 Molecular and Clinical Sciences Institute, St. George’s 
University of London, Cranmer Terrace, London SW17 0RE, 
UK
24 Innovative Medical Research Center, Mashhad Branch, 
Islamic Azad University, Mashhad, Iran
25 Department of Neuromuscular Disorders, UCL Queen 
Square Institute of Neurology, London WC1N 3BG, UK
26 Department of Paediatric Neurology, Children’s Hospital 
and Institute of Child Health, Multan 60000, Pakistan
27 CENTOGENE AG, Rostock, Germany
28 Department of Pediatrics, Tawam Hospital, and College 
of Medicine and Health Sciences, UAE University, Al-Ain, 
UAE
29 Department of Neurosciences, King Faisal Specialist 
Hospital and Research Centre, Riyadh 11211, 
Kingdom of Saudi Arabia
30 Neurology Division, Department of Pediatrics, College 
of Medicine, King Saud University, Riyadh 11461, 
Kingdom of Saudi Arabia
31 Department of Pathology and Laboratory Medicine, 
King Faisal Specialist Hospital and Research Centre, 
Riyadh 11211, Kingdom of Saudi Arabia
 Acta Neuropathologica
1 3
32 Radiology Department, King Faisal Specialist 
Hospital and Research Centre, Riyadh 11211, 
Kingdom of Saudi Arabia
33 Obstetrics/Gynecology Department, King Faisal 
Specialist Hospital and Research Centre, Riyadh 11211, 
Kingdom of Saudi Arabia
34 Department of Cell Biology, King Faisal Specialist 
Hospital and Research Centre, Riyadh 11211, 
Kingdom of Saudi Arabia
35 Department of Biostatistics, Epidemiology and Scientific 
Computing, King Faisal Specialist Hospital and Research 
Centre, Riyadh 11211, Kingdom of Saudi Arabia
36 Medical Genetics Research Center, Shahid Sadoughi 
University of Medical Sciences, Yazd, Iran
37 Yazd Reproductive Sciences Institute, Shahid Sadoughi 
University of Medical Sciences, Yazd, Iran
38 Diabetes Research Center, Shahid Sadoughi University 
of Medical Sciences, Yazd, Iran
39 Department of Neurosurgery, Program On Neurogenetics, 
Yale School of Medicine, Yale University, New Haven, CT, 
USA
40 Masonic Medical Research Institute, Utica, NY, USA
41 Department of Pediatrics, Pediatric Neurology Clinic, 
Choithram Hospital and Research Centre, Indore, 
Madhya Pradesh, India
42 Pediatric Gastroenterology Department, Children’s Hospital 
and Institute of Child Health, Lahore, Pakistan
